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A B S T R A C T
Background
Despite indications from epidemiological trials that higher blood glucose concentrations are associated with a higher risk for developing
micro- and macrovascular complications, evidence for a beneficial effect of antihyperglycaemic therapy in patients with type 2 diabetes
mellitus is conflicting. Two large studies, theUnited Kingdom ProspectiveDiabetes Study (UKPDS) and the University GroupDiabetes
Program (UGDP), did not find a reduction of cardiovascular endpoints through improvement of metabolic control. The theoretical
benefits of newer insulin analogues might result in fewer macrovascular and microvascular events.
Objectives
To assess the effects of long-term treatment with long-acting insulin analogues (insulin glargine and insulin detemir) compared to NPH
insulin in patients with type 2 diabetes mellitus.
Search methods
Studies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library and communication with experts
in the field as well as insulin producing companies.
Selection criteria
Studies were included if they were randomised controlled trials in adults with diabetes mellitus type 2 and had a trial duration of at
least 24 weeks.
Data collection and analysis
Two authors independently assessed trial quality and extracted data. Pooling of studies by means of random-effects meta-analyses was
performed.
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Main results
Six studies comparing insulin glargine to NPH (Neutral Protamine Hagedorn) insulin and two studies comparing insulin detemir to
NPH insulin were identified. In these trials, 1715 patients were randomised to insulin glargine and 578 patients to insulin detemir.
Duration of the included trials ranged from 24 to 52 weeks. Metabolic control, measured by glycosylated haemoglobin A1c (HbA1c)
as a surrogate endpoint, and adverse effects did not differ in a clinical relevant way between treatment groups. While no statistically
significant difference for severe hypoglycaemia rates was shown in any of the trials, the rate of symptomatic, overall and nocturnal
hypoglycaemia was statistically significantly lower in patients treated with either insulin glargine or detemir. No evidence for a beneficial
effect of long-acting analogues on patient-oriented outcomes like mortality, morbidity, quality of life or costs could be obtained.
Authors’ conclusions
Our analysis suggests, if at all only a minor clinical benefit of treatment with long-acting insulin analogues for patients with diabetes
mellitus type 2 treated with “basal” insulin regarding symptomatic nocturnal hypoglycaemic events. Until long-term efficacy and safety
data are available, we suggest a cautious approach to therapy with insulin glargine or detemir.
P L A I N L A N G U A G E S U M M A R Y
Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
NPH (Neutral Protamine Hagedorn) insulin is the current standard for basal insulin in the blood glucose lowering therapy in people
with type 2 diabetes mellitus. The mode of action of this insulin is highly variable, which may be the cause for the difficulties some
people with diabetes have to achieve current goals for long-term metabolic control. Therefore, new insulins which are thought to show
more favourable properties of action have been developed: insulin glargine and insulin detemir. Because of their theoretical advantages,
it is thought that treatment with these new insulin analogues might lead to a beneficial effect, for example less hypoglycaemia or a
better metabolic control, possibly resulting in higher quality of life and treatment satisfaction less late diabetic complications such as
problems with eyes, kidneys or feet and myocardial infarction, stroke or death.
Although epidemiological studies indicate that high concentrations of blood glucose carry a higher risk for these late complications,
evidence for a beneficial effect of glucose-lowering therapy is conflicting. Following from the different results of large clinical trials,
interventions seem to carry different substance specific beneficial or adverse effects. As a consequence, conclusions on the effects of
different blood glucose lowering interventions on these outcomes can not be drawn from their effect on blood glucose concentration
alone.
Methodological quality of all the studies was rated low (“C”). Eight studies investigated altogether 2293 people. Trials lasted between
24 and 52 weeks. Our analysis of the currently available long-term trials comparing long acting insulin analogues with NPH insulin
showed that insulin glargine and insulin detemir were almost identically effective compared to NPH insulin in long-term metabolic
control (HbA1c). Fewer people experienced symptomatic overall or nocturnal hypoglycaemic episodes with treatment with either of
the two analogues. No conclusive information on late complications or on possible differences in the number of fatalities exists. For
insulin glargine one study found a higher rate of progression of diabetic retinopathy in patients treated with insulin glargine, while in
another investigation the opposite result was found. It was thus not possible to conclude for certain whether insulin glargine treatment
is safe or not. From the retrieved trials it was also not possible to draw firm conclusions on the effects of these new insulins on quality
of life or their cost effectiveness. Until long-term data on benefit and risk are available, we suggest a cautious approach to treatment
with insulin glargine or insulin detemir.
B A C K G R O U N D
Description of the condition
Diabetes mellitus type 2 is a metabolic disorder characterised by
relative insulin deficiency resulting from a reduced sensitivity of
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tissues to insulin or an impairment of insulin secretion by pancre-
atic beta cells or both. This in turn leads to chronic hyperglycaemia
(that is elevated levels of plasma glucose) with disturbances of car-
bohydrate, fat and protein metabolism. Long-term complications
of diabetes mellitus include retinopathy, nephropathy, neuropathy
and increased risk of cardiovascular disease. For a detailed overview
of diabetes mellitus, please see ’Additional information’ in the in-
formation on the Metabolic and Endocrine Disorders Group in
The Cochrane Library (see ’About the Cochrane Collaboration’,
’Collaborative Review Groups (CRGs)’). For an explanation of
methodological terms, see the main Glossary in The Cochrane Li-
brary.
Description of the intervention
Even though epidemiological investigations indicate that higher
blood glucose concentrations are associated with a higher risk for
developing micro- and macrovascular complications (Adler 1997;
Klein 1995; Turner 1998), evidence for a beneficial effect of an-
tihyperglycaemic therapy is conflicting. In the past, investigations
of different pharmacological interventions showed results from a
marked risk reduction of microvascular complications (Ohkubo
1995), a reduction of macrovascular risk without a difference in
blood glucose concentrations (UKPDS 34 1998) to a statistically
non significant (Abraira 1997) and even statistically significant
(UKPDS 34 1998) risk increase for macrovascular complications.
Following from these results, it has to be assumed that the dif-
ferent interventions carry different substance specific beneficial or
adverse effects. As a consequence, firm conclusions on the effect
of interventions on patient-relevant outcomes can not be drawn
from the effect of these interventions on blood glucose concentra-
tion alone.
Pharmacological anti-hyperglycaemic therapy in patients with
type 2 diabetes mellitus can be done either by different oral agents
or insulin. Insulin in itself is a group of heterogeneous prepara-
tions clinically differentiated by their course of action over time.
While short-acting insulin is used to mimic the response of en-
dogenous insulin to food intake and to correct pre- or between-
meal hyperglycaemia (bolus insulin), intermediate and long-acting
insulin is primarily used to provide a continuous supply of small
amounts of insulin, independent of food intake, over a longer pe-
riod of time to regulate lipolysis and the output of hepatic glucose
(basal insulin). long-acting insulin preparations are obtained by
crystallisation with either protamine (NPH type) or zinc (Lente
type). Treatmentwith these basal insulins however does show some
drawbacks. Achieving lower blood glucose levels carries an in-
creased risk for hypoglycaemia. Because NPH, the most widely
used basal insulin, is associated with a pronounced insulin peak
following injection and variable absorption (Heinemann 2000;
Lepore 2000), targeting for lower glycosylated haemoglobin A1c
(HbA1c) levels is often difficult and leads to an increased rate of
hypoglycaemic events.
In an effort to provide insulin with a more physiological time
course of action to patients with diabetes mellitus, so called insulin
analogues have been developed. Insulin analogues are insulin-like
molecules, engineered on the basis of the human insulin molecular
structure by changing the amino acid sequence and the physio-
chemical properties. Two such long-acting insulin analogues, in-
sulin detemir (Levemir®) and insulin glargine (Lantus®) are cur-
rently available on the market.
Based on the altered time-actionprofiles of these insulin analogues,
different possible advantages in the therapy of diabetic patients
were suggested. For instance it was proposed that a lower HbA1c
could be achievedwith a simultaneous lower risk of hypoglycaemia
due to the longer action (lower fasting plasma glucose) and the
less pronounced peak (less hypoglycaemia especially during the
night). It was also hypothesised that use of Insulin glargine or
detemir could improve the patient’s quality of life and treatment
satisfaction.
Adverse effects of the intervention
Comparing human insulin with insulin analogues has shown a
higher mitogenic potency and IGF binding affinity for some rep-
resentatives of the group of insulin analogues in in-vitro and ani-
mal studies (Grant 1993; Jorgensen 1992; King 1985; Kurtzhals
2000). These effects differ among the individual insulin analogues
and results provided from these studies cannot clarify the rele-
vance for patients with diabetes mellitus. The American and the
European pharmaceutical registration agencies FDA and EMEA
(EMEA 2003; EMEA 2004; FDA 2000; FDA 2005) have com-
mented on themitogenic and carcinogenic potency of long-acting
insulin analogues and conclude that the detrimental effects seems
to be low. However, it must be noted that the clinical relevance
for patients remains unknown.
How the intervention might work
Insulin glargine is produced by substituting glycine for asparagine
at position 21 of the A-region of the insulin molecule and the
addition of two arginine molecules at position B30. This leads to
a shift of the isoelectric point toward a neutral pH, resulting in a
molecule which is less soluble at the injection site and forms an
amorphous precipitate in the subcutaneous tissue which is grad-
ually absorbed. From this depot insulin molecules are slowly re-
leased. Metabolic activity of insulin glargine has been shown in
pharmacodynamic studies to last for 22 (Lepore 2000) and 30
(Heinemann 2000) hours and to have no peak (Lepore 2000).
Different from this time course of action, NPH insulin, currently
the most widely used basal-insulin, reaches a peak between four
and eight hours with a duration of action of 12 to 14 hours (Lepore
2000). Variation among study participants in the rates of glucose
infusion required to maintain euglycaemia after injection has also
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been found to be lower with insulin glargine than with both NPH
and zinc insulin (Lepore 2000).
Compared to human insulin, the amino acid threonin at position
30 of the B-region has been omitted and a fatty acid acylated to
lysin at position B 29 in insulin detemir. These modifications lead
to a self association at the injection site and allow insulin detemir
to reversibly bind to the fatty acid binding sites of albumin. Both of
these mechanisms seem to be responsible for the slow absorption
from the subcutaneous tissue and thus the protracted action of
this insulin analogue (Havelund 2004). Also, euglycaemic clamp
studies in type 1 diabetic patients showed a lower degree of intra
patient variability of action compared with NPH insulin and in-
sulin glargine (Heise 2004).
Why it is important to do this review
Several publications have evaluated the clinical efficacy of in-
sulin glargine and insulin detemir in the treatment of patients
with type 2 diabetes mellitus. Also, various reviews on this sub-
ject have been conducted. These reviews considered either only
glargine (CCOHTA Glargine 2004; Dunn 2003; National 2002;
Rosenstock 2005) or insulin detemir (CCOHTA Detemir 2004;
Chapman 2004) or were published before new studies on these
new insulin analogues became available.
While from their pharmacokinetic profile, long-acting insulin ana-
logues appear to be an improvement in the insulin therapy of pa-
tients with diabetes mellitus, their superiority in the clinical set-
ting has still to be proven. The aim of this work is to systemati-
cally review the clinical efficacy and safety of insulin glargine and
detemir in the treatment of patients with type 2 diabetes mellitus.
O B J E C T I V E S
To assess the effects of long-term treatment with long-acting in-
sulin analogues (insulin glargine and insulin detemir) compared
to NPH insulin in patients with type 2 diabetes mellitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials with parallel or cross-over design,
blinded or open-label with a duration of 24 weeks or longer. Re-
ports of which no full publication exists were considered for inclu-
sion in this review only, if the information available would allow
for a publication in accordance with all criteria of the CONSORT
statement.
Types of participants
People with type 2 diabetes mellitus.
Types of interventions
Comparison of long-acting insulin analogues (insulin glargine or
insulin detemir) to NPH insulin. In case of a combination therapy
(long-acting insulin analogue combined with another antihyper-
glycaemic drug) the additional antihyperglycaemic agent had to
be part of each treatment arm. Only studies reporting on insulin
scheme with subcutaneous application were considered for inclu-
sion in this review.
Types of outcome measures
Primary outcomes
• number of overall, severe and nocturnal hypoglycaemia;
• glycaemic control as measured by glycosylated haemoglobin
A1c (HbA1c).
Secondary outcomes
• mortality (total, diabetes specific and cardiovascular);
• cardiovascular morbidity (for example myocardial
infarction, stroke, heart failure, revascularization procedures);
• diabetic late complications: renal failure, amputation,
blindness or worsening of retinopathy;
• quality of life measured with a validated instrument;
• adverse events;
• costs.
Covariates, effect modifiers and confounders
Comparability of the antihyperglycaemic therapeutic scheme.
Search methods for identification of studies
Electronic searches
Published studies were identified through a literature search using
• The Cochrane Library (including the Cochrane Controlled
Trials Register (CENTRAL)),
• MEDLINE,
• EMBASE, and the CRD Databases (DARE, NHSEED,
HTA) via Ovid Web Gateway.
For detailed search strategies please see under Appendix 1.
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Searching other resources
We also searched the reference lists of included trials and reviews.
Handsearching was done by using cross-references from original
articles and reviews.
Further searches
for published or unpublished studies were carried out in registries
of clinical trials at http://www.clinicalstudyresults.org and http://
www.clinicaltrials.gov.
We further on searched publicly accessible documents at the Euro-
pean Medicines Agency (EMEA) at http://www.emea.eu.int and
the Food and Drug Administration (FDA) at http://www.fda.gov.
Information on unpublished trials was sought fromSanofi-Aventis
Pharmaceuticals (producer of insulin glargine) and Novo Nordisk
(producer of insulin detemir)
Data collection and analysis
Selection of studies
Two authors independently screened the title and abstract of each
reference identified by the search and applied the inclusion crite-
ria. Interrater agreement was calculated using the kappa-statistic
(Cohen 1960). Articles that appeared to fulfil the inclusion cri-
teria were retrieved in full. In case of disagreement between the
two authors, the full article was obtained and inspected indepen-
dently by the two authors. Where differences in opinion existed,
the differences were resolved by a third party. If a resolution of
the disagreement was not possible, the article was added to those
’awaiting assessment’ and the authors of the study were contacted
for clarification.
Data extraction and management
Data from each included study were extracted by two independent
authors using our data extraction form. Differences in data ex-
traction were resolved by consensus, referring back to the original
article. When necessary, information was sought from the authors
of the primary studies. Our data extraction form was headed by
the identification of the trial, the name of the first author, the year
in which the trial was first published and the quality assessment
criteria. The following data were extracted, checked and recorded:
1. General Information
The general information included the publication status (pub-
lished or unpublished), if it was a duplicate publication, the spon-
sor of the trial (specified, known or unknown), the language of
publication, the country of publication, the geographical area (ur-
ban or rural) and the setting where the trial was carried out (hos-
pital inpatient, hospital outpatient, general practice).
2. Methods Section
The information about the methods summarised the characteris-
tics of the trial, the characteristics of participants, the characteris-
tics of interventions and the outcome measures used and reported
in the publication.
2.1. Characteristics of the trial
The reported items included the design and duration of the
trial, randomisation (and method), allocation concealment (and
method), blinding (patients, people administering treatment, out-
come assessors) and the check of blinding.
2.2. Characteristics of participants
Information about the participants included the number of partic-
ipants in each group, how the participants were selected (random,
convenience), the exclusion criteria used and the general charac-
teristics (e.g. age, gender, nationality, ethnicity). Disease related
information concerning duration of diabetes and late complica-
tions such as retinopathy, nephropathy, neuropathy and foot com-
plications was extracted. The similarity of groups at baseline was
checked as well as reports about withdrawals and losses to follow-
up (reasons / description). If subgroup analysis was done, the re-
ported reasons and the method were noted.
2.3. Characteristics of interventions
The relevant information to extract were the time of intervention,
the length of follow-up (in months), the types of insulin (long-
acting analogues versus NPH), the dose and route of administra-
tion and the administration schedule.
2.4. Characteristics of outcome measures
The measures mentioned in the outcome section and any other
outcomes measured in the study were reported.
Assessment of risk of bias in included studies
Trials fulfilling the review inclusion criteria were assessed indepen-
dently by two authors to evaluate methodological quality. Inter-
rater agreement was calculated using the kappa-statistic (randomi-
sation, allocation concealment, blinding). Again, any differences
in opinion were resolved by discussion with a third author. As-
sessment for methodological quality was done using a modifica-
tion of the criteria given in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2005) and the criteria of Jadad
and Schulz (Jadad 1996; Schulz 1995) and was made based on the
following criteria:
(1) Minimisation of selection bias: - a) was the randomisation
procedure adequate? - b)was the allocation concealment adequate?
(2) Minimisation of performance bias: - a) were the patients and
people administering the treatment blind to the intervention?
(3)Minimisation of attrition bias: - a) were withdrawals and drop-
outs completely described? - b) was analysis done by intention-to-
treat?
(4) Minimisation of detection bias: - a) were outcome assessors
blind to the intervention?
Based on these criteria, studies were subdivided into the following
three categories as set forth by the Cochrane Handbook for System-
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atic Reviews of Interventions (Higgins 2005):
A - all quality criteria met: low risk of bias.
B - one or more of the quality criteria only partly met: moderate
risk of bias.
C - one or more criteria not met: high risk of bias.
For the purpose of the analysis in this review, trials were included
if they meet the criteria A, B or C according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2005;
Kunz 1998) (see also sensitivity analysis below). Also, individual
quality criteria were investigated.
Assessment of heterogeneity
Heterogeneity between trials was assessed by the χ2 -test. Quan-
tification of heterogeneity was also examined with I2, ranging
from 0% to 100% including its 95% confidence interval (Higgins
2002). I2 demonstrates the percentage of total variation across
studies due to heterogeneity and was used to judge the consistency
of evidence. I2 values of 50% and more indicate a substantial level
of heterogeneity (Higgins 2003).
Data synthesis
For the outcome percentage of glycosylated haemoglobin A1c
(HbA1c), the change between baseline and endpoint was used
for the comparison between the two groups. Weighted mean dif-
ferences (WMD) were calculated using a random-effects model
for the meta-analysis. In some studies the mean change and its
variance for each group were presented in the published report of
the trial. In other cases where these estimates were not reported,
we had to calculate appropriate variances, if possible, from other
statistics presented. We also took a second approach to assess the
robustness of the results. We calculated a pooled estimate of the
variance of change between baseline and endpoint from trials for
which the correctly calculated values were reported.
Furthermore, we looked at patients with at least one episode of
(severe, nocturnal, symptomatic and overall) hypoglycaemia. For
themeta-analysis of severe hypoglycaemic episodes, the Peto-Odds
Ratio was used, since the event rates were low. In all other cases a
random-effects meta-analysis of the relative risk was performed.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to explore the possible
effect size differences for:
• different types of insulin analogues (glargine versus
detemir).
• different additional anti hyperglycaemic therapy such as
oral antidiabetic drugs versus insulin.
• NPH once daily versus NPH twice daily.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on effect size:
• repeating the analysis excluding unpublished studies;
• repeating the analysis restricting for study quality;
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results;
• repeating the analysis excluding studies using the following
filters: language of publication, source of funding (industry
versus other).
The robustness of the results was also planned to be tested by
repeating the analysis using different measures of effect size (risk
difference, odds ratio etc.) and different statistical models (fixed
and random-effects models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The search in the electronic databases yielded 2065 records, of
which 818 could be excluded as duplicates.Of the remaining 1247
publications, 1228 were excluded by consensus as not relevant to
the question under study on the basis of their abstracts and 19
were identified for further examination. One additional publica-
tion of potential relevance, not listed in the electronic databases,
was identified through communication with insulin producing
companies (Kawamori 2003). No studies were identified through
inquiries addressed to experts in the field, EMEA, FDA and reg-
istries of clinical trials. After screening the full text of the selected
publications, 11 publications on nine studies finally met the in-
clusion criteria (see Figure 1 for details of the QUOROM (quality
of reporting of meta-analyses) statement)).
All relevant studies were published after the year 2000 and written
in English.
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Figure 1. QUOROM (quality of reporting of meta-analyses) flow-chart of study selection
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Assessment of publication bias interrater agreement
Interrater agreement for study selection, that is qualifying a study
as “included” or “potentially relevant” was 99%.
Studies awaiting assessment
Through communication with Sanofi-Aventis we became aware
of one additional study comparing insulin glargine with NPH in-
sulin in patients with type 2 diabetes mellitus (Kawamori 2003),
which was not listed in any of the electronic databases searched.
Unfortunately, the publication was not available in time for in-
clusion in this review. We therefore will assess its relevance in the
next update of this review.
Included studies
Interventions
Comparisons
Of the nine included studies seven investigated the compara-
ble effects of insulin glargine (Eliaschewitz 2006; Fritsche 2003;
Massi 2003; Rosenstock 2001; Riddle 2003; Yki-Järvinen 2006;
Yokoyama 2006) and NPH insulin and two studies insulin de-
temir (Haak 2005; Hermansen 2006) versus NPH insulin, either
in combination with oral antidiabetic drugs (OADs) (Eliaschewitz
2006; Fritsche 2003; Hermansen 2006; Massi 2003; Riddle
2003; Yki-Järvinen 2006) or a short-acting insulin (Haak 2005;
Rosenstock 2001) or both (Yokoyama 2006).
The design of the investigation by Yokoyama 2006 required an
upward titration of insulin glargine with a target of a fraction of
50% of the basal insulin on the total daily insulin requirement.
In contrast to this, the fraction of NPH on the total daily insulin
requirement was left unchanged, thus introducing a difference in
the treatments of the two comparison groups, making the study
unfit to answer the question of substance specific differences of
insulin glargine and NPH insulin. Even though this was the case,
we were not able to exclude this study formally on the basis of the
prespecified exclusion criteria. We therefore present this investiga-
tion in the table Characteristics of included studies and in Table 1,
Appendix 2, Appendix 3, Appendix 4, Appendix 5 and Appendix
6; but did not consider it for the meta-analyses, nor discuss it any
further.
Glargine versus NPH
One study (Fritsche 2003) compared two interventional arms
with different insulin schedules, glargine in the morning and at
bedtime, versus NPH at bedtime. In all the other studies in-
sulin glargine was injected at bedtime. NPH was given once daily
at bedtime in all investigations with the exception of one study
(Rosenstock 2001) in which NPH could be applied at bedtime or
twice daily (at bedtime and in the morning):
• Fritsche 2003 glargine at morning plus 3 mg glimepiride
versus NPH at bedtime plus 3 mg glimepiride;
• Fritsche 2003 glargine at bedtime plus 3 mg glimepiride
versus NPH at bedtime plus 3 mg glimepiride;
• Massi 2003 glargine at bedtime plus sulphonylurea (SU)
alone or in combination with metformin, acarbose or metformin
alone versus NPH at bedtime plus SU alone or in combination
with metformin, acarbose or metformin alone;
• Riddle 2003 glargine at bedtime plus SU, metformin or
pioglitazone or rosiglitazone versus NPH at bedtime plus SU,
metformin or pioglitazone or rosiglitazone;
• Yki-Järvinen 2006 glargine at bedtime plus metformin
versus NPH at bedtime plus metformin;
• Eliaschewitz 2006 glargine at bedtime plus 4 mg
glimepiride in the morning versus NPH at bedtime plus 4 mg
glimepiride in the morning;
• Rosenstock 2001 glargine at bedtime plus premeal regular
insulin versus NPH at bedtime or at bedtime and in the morning
plus premeal regular insulin.
Two additional publications were identified which reported on the
results for different subgroups of the studies by Massi 2003 and
Rosenstock 2001. In the publication by Yki-Järvinen 2000 the
results on the subgroup of insulin-naive patients from the study
by Massi 2003 are presented. Fonseca 2004 describes the findings
on the subgroup of patients applying insulin only once daily from
the investigation by Rosenstock 2001.
Detemir versus NPH
In both included studies (Haak 2005; Hermansen 2006) in-
sulin detemir as well as NPH insulin was applied once or twice
daily, either in combination with oral antidiabetic drugs (OADs)
(Hermansen 2006) or with premeal insulin aspart (Haak 2005):
• Haak 2005 detemir once daily at bedtime or twice daily at
bedtime and in the morning plus premeal insulin aspart versus
NPH once daily at bedtime or twice daily at bedtime and in the
morning plus premeal insulin aspart
• Hermansen 2006 detemir twice daily plus metformin,
insulin secretagogues or alpha-glucosidase inhibitors versus NPH
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twice daily plus metformin, insulin secretagogues or alpha-
glucosidase inhibitors
Number of study centres
All included trials had amulti-centre design ranging from 7 to 111
centres. Seven studies involvedmore than 50 centres (Eliaschewitz
2006; Fritsche 2003; Haak 2005; Hermansen 2006; Massi 2003;
Riddle 2003; Rosenstock 2001).
Country and location
Four studies were performed in Europe (Fritsche 2003; Haak
2005; Hermansen 2006; Yki-Järvinen 2006), two in North Amer-
ica (Riddle 2003; Rosenstock 2001), one in Europe, one in South
Africa (Massi 2003) and one Latin America (Eliaschewitz 2006).
Setting
None of the publications presented details about the setting.
Treatment before study
Pre-study treatment consisted of OADs in five investigations
(Eliaschewitz 2006; Fritsche 2003; Hermansen 2006; Riddle
2003; Yki-Järvinen 2006), mostly sulfonylureas, metformin and
acarbose. Additionally, glitazones and insulin secretagogues were
each allowed in one study. In another study patients could be
treated with OADs or insulin (Massi 2003) and had to be treated
with insulin in two further studies (Haak 2005; Rosenstock 2001).
Methods
Duration of intervention and duration of follow-up
Most studies had a treatment duration of approximately six
months. One trial (Massi 2003) lasted for 12 months and one
(Yki-Järvinen 2006) for nine months.
Treatment duration and duration of follow-up were identical in
all trials.
Run-in period
Only one study had a formal run-in period (Riddle 2003). All other
studies, with the exception of one (Hermansen 2006) reported on
a screening period of four weeks duration in most cases and 1 to 4
weeks in one study (Rosenstock 2001) and three weeks in another
study (Haak 2005): During this phase, in two investigations (
Eliaschewitz 2006; Fritsche 2003) the treatmentwas changed from
previous oral antihyperglycaemic therapy to glimepiride. In the
publication by Haak 2005 no information was given on possible
changes in treatment. In the rest of the studies patients continued
their ongoing antihyperglycaemic treatment during this screening
phase.
Language of publication
All included publications were published in English.
Participants
Who participated
Only patients with diabetes mellitus type 2 were included in the
studies. Mean duration of diabetes ranged from 8 to 14 years. Par-
ticipants were mostly of Caucasian origin (for those publications
with no information on the ethnic composition of the study pop-
ulation, it can be inferred from the study locations) with mean age
ranging from 55 to 62 years. Most patients were overweight, with
a body mass index (BMI) ranging from 27 to 33 kg/m2. None of
the studies was performed with pharmaco-naive (that is, people
treated with diet or exercise or both only) patients. Metabolic con-
trol in patients randomised to insulin glargine or detemir ranged
from 7.9% to 9.5% glycosylated haemoglobin A1c (HbA1c) at
baseline.
Only one study (Rosenstock 2001) showed a possible clinically
important difference in baseline characteristics. In this investiga-
tion more patients in the NPH group had retinopathy at the be-
ginning of the trial than in the insulin glargine group (for details
see table Characteristics of included studies).
Inclusion criteria
Various inclusion criteria, such as certain HbA1c levels, age and
BMI ranges and pre-study treatment requirements, were specified
by the investigators. Three studies (Eliaschewitz 2006; Fritsche
2003; Hermansen 2006) explicitly chose participants who were
poorly controlled on oral antihypertensive therapy (for details see
table Characteristics of included studies).
Exclusion criteria
Investigators specified various exclusion criteria. In two stud-
ies (Haak 2005; Hermansen 2006) patients with proliferative
retinopathy ormaculopathy requiring treatment and in one (Massi
2003) patients with retinopathy who have received surgical treat-
ment or would require surgical treatment within three months
were excluded. In two publications (Haak 2005; Hermansen
2006) a history of recurrent major hypoglycaemia and hypogly-
caemia unawareness (Hermansen 2006; Riddle 2003) were listed
among exclusion criteria (for details see table Characteristics of
excluded studies).
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Diagnostic criteria
None of the included studies explicitly reported diagnostic criteria.
Outcomes
Primary outcomes
Seven studies investigated HbA1c, either at endpoint or change
from baseline to endpoint and one (Riddle 2003) the percent-
age of patients achieving HbA1c equal to or less than 7.0% with-
out symptomatic nocturnal hypoglycaemia as primary outcome.
Fritsche 2003 also lists the frequency of patients experiencing hy-
poglycaemia as a primary outcome.
Secondary and additional outcomes
Most studies evaluated the frequency of overall or symptomatic,
severe and nocturnal hypoglycaemia, fasting plasma glucose
(FPG), blood glucose (BG) profiles, insulin doses, body weight
and adverse events as further outcomes (for details see ta-
ble Characteristics of included studies). Two investigations (
Eliaschewitz 2006; Fritsche 2003) compared the percentage of
patients achieving a HbA1c equal to or less than 7.5% and one
(Hermansen 2006) the percentage of patients achieving a HbA1c
equal to or less than 7.0% without hypoglycaemia as a secondary
outcome (for details see table Characteristics of included studies).
Hypoglycaemia
All studies investigating insulin glargine versus NPH insulin re-
ported data on severe, symptomatic and nocturnal hypoglycaemic
events. From the two trials comparing insulin detemir with NPH
insulin results for severe, overall and nocturnal hypoglycaemic
events were available.
In all included studies neither the participants nor the caregivers
were blinded. Therefore, the reliability of the results revealed is
heavily dependent on how much room the definition of hypogly-
caemic events in the studies leaves for subjective interpretation or
deliberate or non-deliberate exertion of influence. Since symptoms
without blood glucose measurements were sufficient for count-
ing an event as hypoglycaemia in all studies, it is not possible to
exclude bias for any reported results on hypoglycaemia. This is
also true for severe hypoglycaemic events because the criterion of
“requirement of assistance from another person” alone is also sus-
ceptible to bias.
The definition of hypoglycaemic events as given in the methods
sections or as reported in the different publications are listed in
Table 1 alongside with our appraisal of possible bias.
None of the studies reported on blinded outcome assessment,
which would be one method for minimisation of possible detec-
tion bias.
Excluded studies
Eight studies were excluded upon further scrutiny. Reasons for ex-
clusion were: not a randomised controlled trial, not a comparable
co-intervention and no individuals with type 2 diabetes mellitus
included (see Characteristics of excluded studies).
Risk of bias in included studies
For details on methodological quality of included studies see
Appendix 6.
All included studies were parallel trials. No cross-over studies or
trials with factorial design fulfilling the inclusion criteria were
identified by the search. Two studies (Riddle 2003; Yki-Järvinen
2006) had a superiority design, one (Eliaschewitz 2006) an equiv-
alence and two (Haak 2005; Hermansen 2006) a non-inferiority
design. In the equivalence and non-inferiority trials equivalence
intervals ranging from 0.4% (Haak 2005; Hermansen 2006) to
0.5% (Eliaschewitz 2006) HbA1c were specified. For three stud-
ies (Fritsche 2003; Massi 2003; Rosenstock 2001) the hypothesis
remained unclear.
Interrater agreement for the key quality indicators randomisation,
concealment of allocation and blinding was 100%.
All included studies were rated as being of insufficient method-
ological quality (“C”). Mostly, this was due to the poor quality of
key methodological elements or poor reporting on them.
Allocation
All included studies were randomised controlled trials and ran-
domised individuals. Reporting onmethods of randomisation was
poor in most of the trials. The method of randomisation was ad-
equate in one study Haak 2005 and specified somewhat in three
(Fritsche 2003; Massi 2003; Riddle 2003) and described in more
detail in one publication (Yki-Järvinen 2006).
The method of concealment of allocation was adequate in five
studies (Haak 2005; Hermansen 2006; Massi 2003; Riddle 2003;
Rosenstock 2001) and unclear in the other three. For one study
(Haak 2005) information on both items was available through
personal communication.
Blinding
Participants or caregivers were not blinded to the treatment in any
of the studies. None of the publications contained information on
possible blinded outcome assessment. Even if blinding seems to
be hard in such trials because insulines glargine and detemir are
clear solutions while NPH insulin is of milky appearance, the fact
remains that an open design, especially with no blinded outcome
assessment and poor or unclear concealment of allocation, carries
an increased risk for bias.
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Incomplete outcome data
Intention-to-treat, per-protocol analyses and missing data
In all investigations main analyses used an intention-to-treat ap-
proach, which was clearly defined in six publications. Even though
none of the studies included all randomised patients in the analyses
(so that they are not, in a strict sense, intention to treat analyses) the
difference between randomised and analysed patients was so small
in four studies (Fritsche 2003; Riddle 2003; Hermansen 2006;
Yki-Järvinen 2006) that no substantial problems should arise from
this fact. For one study (Haak 2005) the difference between the
number of randomised and analysed patients was considerable.
In three publications (Massi 2003; Rosenstock 2001; Eliaschewitz
2006) the number of analysed patients was not reported.
A per-protocol analysis was reported for one study with an equiv-
alence (Eliaschewitz 2006) design and one with a non-inferiority
design (Hermansen 2006), but not for the second investigation
with a non-inferiority analysis (Haak 2005).
For analyses in four studies (Eliaschewitz 2006; Hermansen 2006;
Riddle 2003; Rosenstock 2001) last observation carried forward
(LOCF) was used formissing data. LOCFwas defined in only four
of these publications (Eliaschewitz 2006;Hermansen2006;Riddle
2003; Rosenstock 2001). For the four investigations it remained
unclear how missing data were considered for the analyses.
Screened and randomised patients
The number of screened patients was available for all studies. Alto-
gether, in the studies included in this review, approximately 1715
patients were randomised to insulin glargine and 578 patients to
insulin detemir. The largest study investigating insulin glargine
included a total of 764 patients, the smallest 110 patients. The
studies on insulin detemir included a total of 505 and 476 pa-
tients.
Discontinuing participation and attrition rates
All studies on insulin glargine described discontinuing patients
and provided at least some details on the reasons for terminating
the trial. Discontinuation rates in the glargine arms varied from
1.6% to 10.2%. The rate of patients discontinuing participation
was dissimilar between the treatment arms in three (Eliaschewitz
2006; Fritsche 2003; Rosenstock 2001) of these studies. In all of
these cases the rate was lower in the NPH arm.
One study reporting on insulin detemir (Haak 2005) showed a
higher rate of discontinuation in the insulin detemir group, while
in the second study the discontinuation rate was 4.2% in the de-
temir arm and similar (though slightly higher) for patients treated
with NPH insulin.
Other potential sources of bias
Definition of primary and secondary endpoints
Primary endpoints were clearly defined in all the studies. In
one publication (Fritsche 2003) two primary endpoints were de-
scribed.
The number of further endpoints reported varied between four
and 11; additional endpoints not described in the methods or
statistics section of the papers were presented inmost publications.
Adjustment for multiple testing was described in one study (Yki-
Järvinen 2006), not done in five (Fritsche 2003; Haak 2005;
Hermansen 2006; Riddle 2003; Rosenstock 2001) and unclear in
two (Massi 2003; Eliaschewitz 2006).
Power calculation
For all studies details of power calculation were reported. The
numbers of participants required ranged from 110 to 375 and
were not known for one publication (Rosenstock 2001).
Compliance measures
None of the publications reported compliance measures, but some
reported that participants were withdrawn because of lack of com-
pliance.
Funding
Five publications reported commercial funding, three (Haak 2005;
Hermansen 2006; Rosenstock 2001) did not indicate funding
sources.
Publication status
All studies were published in peer review journals. None was cir-
culated as a journal supplement.
Effects of interventions
Because it is not possible to include a comparison group twice in
the same meta-analysis we could not consider all treatment arms
from the Fritsche study (Fritsche 2003) for the meta-analyses. For
reasons of homogeneity, only the comparison of glargine in the
evening versus NPH in the evening was included in our analyses.
Glycosylated haemoglobin A1c (HbA1c)
HbA1c values were available in all studies for verification of
metabolic control. For the meta-analysis the difference in change
of HbA1c from baseline to study endpoint was chosen as the out-
come of interest.
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Glargine versus NPH
In two studies (Eliaschewitz 2006; Fritsche 2003) with three com-
parisons, the change in HbA1c from baseline to endpoint and
measures of variance for each treatment arm were reported. One
study (Rosenstock 2001) presented adjusted values for the HbA1c
change andmeasures of variance. In two publications (Massi 2003;
Riddle 2003) the changes of HbA1c but no measures of vari-
ances were reported. For one investigation (Yki-Järvinen 2006) the
change inHbA1c was calculated from the given figures for HbA1c
at baseline and endpoint; values for SD were also calculated for
this study.
Meta-analyses were performed:
(1) including only studies for which relevant data were either
available or could be calculated based on information in the
study report (Eliaschewitz 2006; Fritsche 2003; Rosenstock 2001;
Yki-Järvinen 2006). The weighted mean difference of change of
HbA1c from baseline to study endpoint was estimated to be 0.1%
(95% confidence interval (CI) -0.1 to 0.2; P = 0.49) in favour of
NPH. The test of heterogeneity yielded a P value of 0.41 (I2 =
0%).
(2) including all studies (Eliaschewitz 2006; Fritsche 2003; Massi
2003; Riddle 2003; Rosenstock 2001; Yki-Järvinen 2006) using
pooled values for SD, for further confirmation of the above result:
The weighted mean difference of change of HbA1c from baseline
to study endpoint was estimated to be 0.00% (95% CI -0.1 to
0.1; P = 0.93). The test of heterogeneity gave a P-value of 0.43 (I
2 = 0%).
The second comparison of the Fritsche study (Fritsche 2003)
showed that reduction ofHbA1c frombaseline to end of study was
significantly greater in patients administering insulin glargine in
the morning versus patients injecting NPH insulin in the evening.
For the subgroup of insulin-naive patients in the study by Massi
2003, no statistically significant differences were found for the
change of HbA1c or HbA1c at endpoint (Massi 2003). Also, the
differences in HbA1c at endpoint and in the change of HbA1c
were not statistically significant different for the subgroup of pa-
tients applying insulin NPH only once daily in the investigation
by Rosenstock 2001 (Rosenstock 2001).
Detemir versus NPH
For one study (Haak 2005) the changes of HbA1c from baseline
to endpoint were reported without measures of variances. Values
for HbA1c at baseline and endpoint are presented in the other
investigation (Hermansen 2006).
Meta-analyses performed:
(1) Change of HbA1c from baseline to endpoint, SDs were calcu-
lated for both studies:
The weighted mean difference of change of HbA1c from baseline
to study endpoint was estimated to be 0.1% (95% CI 0.01 to 0.2;
P = 0.03) in favour of NPH insulin. The test of heterogeneity
gave a P value of 0.46 (I2 = 0%). Even though this result indicates
a statistically significant difference in change of HbA1c between
insulin detemir and NPH insulin, the difference is well inside the
non-inferiority margin of 0.4% HbA1c which both of the studies
specified.
(2) Change of HbA1c from baseline to endpoint, pooled SDs were
used for both studies.
The weighted mean difference of change of HbA1c from baseline
to study endpoint was estimated to be 0.2% (95% CI -0.02 to
0.3; P = 0.08) in favour of NPH insulin. The test of heterogeneity
gave a P value of 0.56 (I2 = 0%).
Hypoglycaemia
Information on hypoglycaemia was available from all included
studies. Reporting on hypoglycaemic events differed in various
aspects: While most studies presented the number of patients or
percentage of patients with hypoglycaemic episodes, only a few
reported frequency of hypoglycaemia as events / patient / time or
as the number of events. Also, the definition of hypoglycaemia
was different between studies. For detailed information on the
various definitions of symptomatic, overall, severe and nocturnal
hypoglycaemic episodes see Table 1. Duration of follow-up was
approximately six months in the majority of the studies and nine
months (Yki-Järvinen 2006) in one study and 12 months (Massi
2003) in another. Since the chance of patients experiencing a hy-
poglycaemic event rises with duration of follow-up, and because
it was not possible to calculate the frequency of hypoglycaemia
as events / patient / time for most of the studies, it was judged
not to be appropriate to include the investigations with follow-up
periods of 9 and 12 months (Yki-Järvinen 2006; Massi 2003) in
the meta-analyses.
Severe hypoglycaemia
For details see Appendix 4.
Glargine versus NPH
Information on severe hypoglycaemia was available from all in-
cluded studies expressed as the number of patients with severe hy-
poglycaemic episodes. Uniformly in all investigations only a few
such episodes occurred. Because of the small number of affected
patients in the meta-analysis the Peto-Odds Ratio was calculated.
The Peto-OR was estimated to be 0.70 (95% CI 0.40 to 1.23) in
favour of insulin glargine. The test of heterogeneity gave a P value
of 0.26 (I2 = 26%).
Results from studies not included in the meta-analysis:
For the second comparison of the Fritsche study (Fritsche 2003)
the incidence of severe hypoglycaemic events was comparable for
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patients applying insulin glargine in the morning and those in-
jecting NPH insulin in the evening. In one of the longer studies
(Yki-Järvinen 2006) no episodes of severe hypoglycaemia were de-
tected during nine months of follow-up. The 12 months, study
(Massi 2003) reported severe hypoglycaemia for 1.7% of patients
treated with insulin glargine and 1.1% of patients treated with
NPH insulin. No information on the statistical significance of this
difference is presented.
Detemir versus NPH
Information on severe hypoglycaemia was available from reported
data for one study (Hermansen 2006) and from data acquired
through personal communication for the other study (Haak
2005). The Peto-OR for severe hypoglycaemia was estimated to be
0.50 (95% CI 0.18 to 1.38; P = 0.18) under therapy with insulin
detemir compared to NPH treatment. The test of heterogeneity
gave a P value of 0.2 (I2 = 44%).
Symptomatic and overall hypoglycaemia
For details see Appendix 4.
Glargine versus NPH
Three studies (Eliaschewitz 2006; Fritsche 2003; Rosenstock
2001) reported frequency of symptomatic hypoglycaemia as the
number or the percentage of patients with events, and could be
included in the meta-analysis. The relative risk was 0.84 (95%
CI 0.75 to 0.95; P = 0.005) in favour of treatment with insulin
glargine. The test of heterogeneity gave a P value of 0.17 (I2 =
44%).
Results from studies not included in the meta-analysis:
In the second comparison of the Fritsche study (Fritsche 2003),
between patients applying insulin glargine in the morning and
those injecting NPH insulin in the evening, no statistically signif-
icant difference in the percentage of patients experiencing symp-
tomatic hypoglycaemic events was found.
One study, reporting event rates only (Riddle 2003), also found
a statistically significant difference in the event rates in favour of
insulin glargine. Event rates were 14 events / patient / year in the
glargine group and 18 events / patient / year in the NPH group,
P < 0.02.
Of the two longer studies, one (Yki-Järvinen 2006) found an event
rate of 5.4 events / patient / year for therapy with insulin glargine
and of 8 events / patient / year for NPH therapy, with a P value for
the difference of event rates of 0.12. The other of the longer stud-
ies (Massi 2003) reported 35% of patients in the glargine group
and 41% of patients in the NPH group affected by symptomatic
hypoglycaemic events. The difference was described as statistically
not significant.
Results for overall hypoglycaemia were reported only for one study
(Fritsche 2003) and thus no meta-analysis was conducted for this
outcome. In the study by Fritsche 2003, 74% of patients treated
with insulin glargine in the morning, 68% of patients treated with
insulin glargine in the evening and 75% of patients treated with
NPH insulin at bedtime experienced at least one episode of hypo-
glycaemia. Neither of the differences was statistically different.
For the subgroup of insulin-naive patients in the study by Massi
2003, Yki-Järvinen reports in her 2001 publication that 33% of
patients treated with insulin glargine and 43% of NPH treated
patients experienced at least one episode of symptomatic hypo-
glycaemia. The difference in frequency of hypoglycaemia between
the two treatment groups was statistically significant (P = 0.04).
Also, in the subgroup of patients applying insulin only once daily
in the study by Rosenstock 2001, reported in the paper by Fon-
seca 2004, fewer patients in the glargine group (15%) experienced
symptomatic hypoglycaemia than in the NPH group (27%).
Detemir versus NPH
Symptomatic hypoglycaemia was reported only in one study (
Hermansen 2006). Reported event rates were 4.9 events / patient
/ year in the detemir group and 9.7 events / patient / year in the
NPH group. The difference was statistically significant: P < 0.001,
RR 0.56 (95% CI 0.42 to 0.74).
Information on overall hypoglycaemia was available from both in-
cluded studies. The meta-analysis yielded a relative risk of 0.82
(95% CI 0.74 to 0.90; P < 0.0001) for treatment with insulin de-
temir versus NPH insulin. No statistically significant heterogene-
ity was detected, P value 0.4 (I2 = 0%).
Symptomatic nocturnal hypoglycaemia
For details see Appendix 4.
Glargine versus NPH
Three studies (Eliaschewitz 2006; Fritsche 2003; Rosenstock
2001) reported frequency of nocturnal hypoglycaemia as the num-
ber or the percentage of patientswith events, and could be included
in the meta-analysis. The relative risk was 0.66 (95% CI 0.55 to
0.80; P < 0.0001) in favour of treatment with insulin glargine.
The test of heterogeneity gave a P value of 0.23 (I2 = 33%).
Results from studies not included in the meta-analysis:
The number of patients experiencing nocturnal hypoglycaemic
events was statistically significantly lower for patients treated with
insulin glargine in the morning compared to patients treated with
NPH insulin in the evening in the Fritsche study (Fritsche 2003).
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The other study reporting event rates only (Riddle 2003) also
found a statistically significant difference in the event rates in
favour of insulin glargine. Event rates were four events / patient /
year in the glargine group and seven events / patient / year in the
NPH group.
Of the two longer studies, one (Yki-Järvinen 2006) did not re-
port on nocturnal hypoglycaemia. The other of the longer studies
(Massi 2003) reported 12% of patients in the glargine group and
24% of patients in theNPH group affected by nocturnal hypogly-
caemic events. The difference was statistically significant, P value
0.0002.
For the subgroup of insulin-naive patients in the study by Massi
2003, Yki-Järvinen reports in her paper from 2001 that 10% of
patients treated with insulin glargine and 24% of NPH treated
patients experienced at least one episode of nocturnal hypogly-
caemia. The difference in frequency of hypoglycaemia between the
two treatment groups was statistically significant, P value 0.0001.
In a second study (Rosenstock 2001), for the subgroup of patients
applying NPH insulin once daily a reduction of the proportion
of patients experiencing nocturnal hypoglycaemia was found for
treatment with insulin glargine (15%) compared to NPH therapy
(27%) (Fonseca 2004).
Detemir versus NPH
Combined results from the two studies showed a relative risk of
0.63 (95%CI 0.52 to 0.76; P < 0.00001) for patients experiencing
at least one nocturnal hypoglycaemic event in favour of insulin
detemir compared to NPH insulin. The test of heterogeneity gave
a P value of 0.88 (I2 = 0%).
Mortality
No study was designed or adequately powered to investigate mor-
tality.
Glargine versus NPH
The number of patients who died during follow-up was reported
in three studies (Eliaschewitz 2006; Fritsche 2003; Massi 2003).
Numbers of events were very small in all cases. Formal statistical
tests were not reported. For details see Appendix 5.
Detemir versus NPH
Data on mortality were available from one study (Haak 2005). In
this study one patient in the insulin detemir treatment group and
no patients in the NPH insulin therapy group died.
Cardiovascular morbidity
Not a single trial reported on cardiovascular morbidity, but from
personal communication data for one study (Haak 2005) investi-
gating the effects of insulin detemir versus NPH insulin became
available. Only a very small number of events occurred during this
trial. Due to this fact no inferences on possible different effects
on cardiovascular morbidity can be drawn from this study. For a
detailed listing see Appendix 5.
Diabetic late complications
There were no reports on diabetic late complications in any of the
trials. For two studies (Massi 2003; Rosenstock 2001) some results
on retinopathy could be found in the FDA reports. In one of these
investigations (Massi 2003) 8.4% of patients in the glargine group
and 14% of patients in theNPH group who had no retinopathy at
baseline developed non-proliferative retinopathy during the study,
and 1.8% versus 2.4% in the respective treatment groups devel-
oped clinically significantmacula oedema. Progressionof retinopa-
thy by more than three stages was seen in 5.9% versus 9.1% of
patients. Development of clinically significant macula oedemawas
found to be statistically not significantly more frequent in patients
treated with insulin glargine with 11.2% of patients affected in
the glargine group and 6.5% of patients in the NPH group, P =
0.1. For this outcome there was a marked difference between pa-
tients without pre-treatment with insulin and insulin pre-treated
patients. While in the former group glargine therapy resulted in a
higher rate of macula oedema with 14% affected versus 4% in the
NPH group, the opposite was found in the subgroup of patients
already treated with insulin before the study: 1.9% versus 12.7%.
Results in the second study (Rosenstock 2001), according to the
FDA report, showed a statistically significant higher rate of pro-
gression of retinopathy by three or more stages in patients treated
with glargine (7.5%) than in patients treated with NPH insulin
(2.7%); P = 0.028.
For one study comparing insulin detemir with NPH insulin (
Haak 2005), results on diabetic late complications were available
through personal communication with the author. But because of
the short duration of the trial only a very few events occurred,
making it impossible to draw any conclusions from results of this
study. A detailed listing of events is presented in Appendix 5.
Quality of life
No trial reported results on quality of life. Only one trial
(Eliaschewitz 2006) reported results on treatment satisfaction with
theDiabetes Treatment and Satisfaction Questionnaire (DTSQc).
In this investigation a statistically significant more pronounced
improvement ofmean scores of treatment satisfactionwas reported
for treatment with insulin glargine versus NPH insulin. While the
DTSQc version measures change, the publication reports baseline
and end of study values for the status version of the DTSQ only.
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Adverse events
For details see Appendix 3.
Some information on adverse events could be derived from all
studies, even though reporting on adverse events was limited.
Due to the differences in duration of follow-up and reporting of
adverse events or lack of data, a meta-analysis was not performed.
Glargine versus NPH
Four studies (Eliaschewitz 2006; Fritsche 2003; Massi 2003; Yki-
Järvinen 2006) presented data concerning the overall number of
patients with events or the number of events. In all these studies
numbers for adverse eventswere comparable for all treatment arms.
Formal statistical testing was not reported in any of the studies.
Results for serious adverse events were reported only in two studies
(Eliaschewitz 2006; Yki-Järvinen 2006) and adverse events possi-
bly related to study medication in four (Eliaschewitz 2006; Massi
2003; Rosenstock 2001; Yki-Järvinen 2006). No important dif-
ferences were found for these events.
The number of patients withdrawing due to adverse events was
reported in another six studies (Eliaschewitz 2006; Fritsche 2003;
Massi 2003; Riddle 2003; Rosenstock 2001; Yki-Järvinen 2006).
Again the numbers were comparable between treatment groups.
Detemir versus NPH
For both studies (Haak 2005;Hermansen 2006) the authors stated
in their publications that no difference in frequency of adverse
events was found between the treatment groups, but no numbers
or formal statistics were reported.
In one study (Haak 2005) the percentage of patients with treat-
ment related events was comparable for both treatments while
the percentage of patients experiencing serious adverse events was
smaller under treatment with insulin detemir. The number of pa-
tients who withdrew from the study because of adverse events was
higher in the insulin detemir group. Numbers of affected patients
in the two latter comparisons are very small. No formal statistical
tests were presented. Also, in the second study (Hermansen 2006)
the authors state that no difference in frequency of adverse events
or the number of patients who withdrew because of adverse events
was found between the treatment groups, but no numbers or for-
mal statistics were reported.
Both studies (Haak 2005; Hermansen 2006) found that patients
under treatment with insulin detemir gained statistically signif-
icant less weight than patients with NPH therapy. The differ-
ence was -0.8 kg in one (Haak 2005) and -1.6 kg in the other
(Hermansen 2006) trial.
Costs
No study reported data on costs of treatment with long-acting
insulin analogues compared to NPH insulin therapy.
Heterogeneity
In all studies except one (Riddle 2003) the number of patients
experiencing severe hypoglycaemic events was lower in the insulin
glargine group. Since differences in the design of the trials or the
definition of severe hypoglycaemia are not a likely explanation and
because numbers of affected patients were very small, a chance
result seems to be the most plausible cause for the different results.
Heterogeneity of results was also found for the frequency of severe
hypoglycaemic events in the trials comparing insulin detemir and
NPH insulin. While the difference in co-medication pre-meal in-
sulin aspart (Haak 2005) or OADs (Hermansen 2006) could be
a possible explanation for this finding, it seems more likely to be
caused by a chance result due to the very small numbers of affected
patients.
Heterogeneity was also found for the magnitude of the reduction
of symptomatic hypoglycaemia. Compared to insulin glargine in
the evening in combination with a sulfonylureas in the morning
(Eliaschewitz 2006; Fritsche B 2003), the treatment with glargine
combined with premeal short-acting insulin (Rosenstock 2001)
resulted in a lower reduction of symptomatic hypoglycaemia. This
difference is likely due to the additional premeal insulin leading
to a higher chance for hypoglycaemia.
Heterogeneity was also detected in the results concerning the dif-
ferences of nocturnal hypoglycaemia in patients treated with in-
sulin glargine versusNPHinsulin. All studies included in themeta-
analysis (Eliaschewitz 2006; Fritsche 2003; Rosenstock 2001)
found a statistically significant reduction in the number of patients
experiencing nocturnal hypoglycaemia for the treatment with in-
sulin glargine. The amount of this reduction was lowest in the
study combining insulin glargine with short-acting premeal in-
sulin (Rosenstock 2001). The additional effect of evening premeal
insulin might be the reason for a higher rate of nocturnal hypo-
glycaemia in this study.
Subgroup analyses
Not performed due to lack of data.
Sensitivity analyses
As for pre-planned sensitivity analyses, those restricting for study
quality and excluding unpublished studies were not done since all
studies were of the same quality “C” and no unpublished trials
were identified. Also, because all publications were in the English
language and not significantly different in size, sensitivity analyses
were not done for these items. The source of funding was commer-
cial in five studies comparing insulin glargine to NPH insulin and
unknown for one study. Since results were not heterogeneous with
known and unknown sources of funding, no sensitivity analysis
was performed. No sensitivity analysis was performed for studies
investigating insulin detemir because only two studies were avail-
able.
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Publication bias
A formal assessment of publication bias was not performed due to
the lack of data. Having considered only papers published in full
text, publication bias cannot be excluded completely.
D I S C U S S I O N
This systematic review and meta-analysis included eight studies
comparing the effects of long-acting insulin analogues to NPH
insulin in patients with type 2 diabetes mellitus. Six studies inves-
tigated insulin glargine and two insulin detemir.
No superiority inHbA1c was observed for insulin glargine. For in-
sulin detemir themeta-analysis yielded a statistically significant but
clinically unimportant superiority of NPH insulin in metabolic
control. Symptomatic and nocturnal hypoglycaemic events were
lower in patients treated with insulin glargine than in patients with
NPH therapy. Also, for insulin detemir the two included studies
found a lower number of patients experiencing overall or nocturnal
hypoglycaemic episodes in the insulin detemir treatment groups.
The methodological quality of the included studies allowed only a
cautious interpretation of the results. Because only a small percent-
age of authors answered our request for additional information as
yet, study quality assessment could not be substantially improved.
Since personal correspondence with authors and companies is an
ongoing process, any future information from these sources will
be incorporated in future updates.
No study designed to investigate possible long-term effects was
found. Therefore, it remains unclear if and to what extent the
treatment with long-acting insulin analogues will affect the de-
velopment and progression of microvascular and macrovascular
events compared to results obtained with NPH insulin. Since the
differences in overall effects on metabolic control were only small
for insulin glargine andNPHand even disadvantageous for insulin
detemir, no important improvements in the development of mi-
crovascular late complications would be expected from treatment
with long-acting insulin analogues.
As for the advantages found in the rate of severe hypoglycaemic
events some caution is warranted. No statistically significant ad-
vantage was found for therapy with insulin glargine or detemir.
Also, interpretation of the results of the frequency of severe hypo-
glycaemia is difficult due to bias-prone definitions. Patients may
inappropriately deny severe hypoglycaemia and in this context
“third party help” is a soft and variable description of severity.More
robust definitions as “injection of glucose or glucagon by another
person” may result in more reliable data (Mühlhauser 1998). In all
studies the frequency of severe hypoglycaemia was very low, mak-
ing it unlikely to see an important clinical effect for the different
treatments.
Even though the meta-analysis found a consistent reduction in
symptomatic or overall hypoglycaemic effects for therapy with
long-acting insulin analogues, no safe inferences can be drawn
from these results because defining hypoglycaemia by symptoms
only makes the results prone to bias, especially in open trials with
(likely) no blinded outcome assessment.
The advantage of insulin glargine and detemir could be a lowering
of nocturnal hypoglycaemic events in patients with type 2 diabetes
mellitus and treatmentwith basal insulin. But again, bias cannot be
ruled out and thus makes the interpretation of the results difficult.
No trial reported data on quality of life. One trial reported
data on treatment satisfaction (Eliaschewitz 2006) and reported a
more pronounced improvement in therapy satisfaction in patients
treated with insulin glargine. The interpretation of the clinical
importance of this result is hindered by the fact that baseline and
end of trial values are reported even though the trialists claim a
statistically significant improvement in the change of treatment
satisfaction. Additionally, the reporting of this outcome was poor
and therefore the assessment of the quality of this outcome was
not possible.
Owing to the maximum observation period of 12 months, this
review cannot provide any further guidance on potential adverse
properties, such as mitogenic effects or progression of microvascu-
lar complications under treatment with long-acting insulin ana-
logues. (For insulin glargine one study found a higher rate of pro-
gression of diabetic retinopathy in patients treated with insulin
glargine, while in another investigation the opposite result was
found.)
Since the mean age of patients in the included studies ranged from
55 to 62 years, no information on possible differences of the effects
of the different insulins in old or in young patients, a growing
group among patients with diabetesmellitus type 2, can be derived
from the studies at hand.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our analysis suggests,if at all only a minor clinical benefit of treat-
ment with long-acting insulin analogues for patients with diabetes
mellitus type 2 treated with “basal” insulin regarding symptomatic
nocturnal hypoglycaemic events. Until long-term efficacy and sa-
fety data are available, we suggest a cautious approach to therapy
with insulin glargine or detemir.
Implications for research
For safety purposes and judgment on the efficacy of long-acting
insulin analogues in terms of diabetic late complications, we need
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a long-term follow-up of larger numbers of patients who use these
insulins. Studies including young and old patients should be con-
ducted. We also suggest a more uniform and more rigorous re-
porting of results from upcoming trials to warrant a better com-
parison and pooling of data and to enable safer inferences from
these results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Eliaschewitz 2006
Methods DURATION OF INTERVENTION: 24 weeks
RUN-IN PERIOD: N; 4 weeks screening phase
LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED: type 2 diabetes patients poorly controlled on OADs
INCLUSION CRITERIA: men or women;age =< 75; BMI =< 35 kg/m²; type 2 diabetes mellitus; failed
to achieve good metabolic control on OADs (HbA1c levels => 7.5% and =< 10.5%; FBG levels => 100
mg/dL; patients required to have been receiving OADs (any sulphonylureas, including glimepiride, or
a combination of sulfonylureas with other OADs such as metformin or acarbose) for at least 6 month;
previous doses of sulfonylureas were required to have been at least equivalent to glimepiride 3 mg; patients
needed to be willing to follow a tight antidiabetic therapy; women of childbearing age needed to use an
acceptable form of contraception
EXCLUSION CRITERIA: previous treatment with any insulin in the three month before the study;
pregnant or breastfeeding, likely to require treatment with drugs not permitted by the study protocol
(non-cardioselective ß-blockers and systemic corticosteroids); enrolment in a previous study of insulin
glargine, received an investigative drug within three month of the study; had a history of alcohol abuse
DIAGNOSTIC CRITERIA: nr
Interventions NUMBER OF STUDY CENTRES: 56
COUNTRY/ LOCATION: Latin American countries
SETTING: nr
INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY): oral, glimepiride 4 mg/day, once
in the morning plus subcutaneous, glargine, once at bedtime
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): oral, glimepiride 4 mg/day, once in the
morning plus subcutaneous, NPH insulin, once at bedtime
TREATMENT BEFORE STUDY: OADs (any sulfonylureas, including glimepiride, or a combination
of sulfonylureas with other OADs such as metformin or acarbose) equivalent to glimepiride 3 mg per day
for at least 6 month
TITRATION PERIOD: 6 weeks
Outcomes PRIMARY OUTCOMES: change in HbA1c from baseline to end of study
SECONDARY OUTCOMES: percentage of patients who achieved a target HbA1c value of =< 7.5% by
the end of the study; change in FBG; percentage of patients who achieved a FBG level =< 100 mg/dL
by the end of the study; treatment satisfaction (DTSQc); pharmacoeconomics; safety
ADDITIONAL PUBLISHED OUTCOMES: unclear
TIMING OF OUTCOME MEASURES: unclear
Notes STATED AIM OF STUDY: To compare the efficacy and safety of basal insulin therapy with insulin
glargine with those of NPH insulin, both in combination with glimepiride in a predominantly non-white
(> 53%) population of patients with type 2 diabetes living in Central and South America
Risk of bias
Item Authors’ judgement Description
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Eliaschewitz 2006 (Continued)
Allocation concealment? Unclear B - Unclear
Fritsche 2003
Methods DURATION OF INTERVENTION:
24 weeks
RUN-IN PERIOD:
4 weeks screening phase; patients discontinued use of previous oral antidiabetic drug treatment and
received 3 mg glimepiride in the morning
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED: patients with type 2 diabetes mellitus, who did not achieve good metabolic
control while receiving oral antidiabetic drugs
INCLUSION CRITERIA: type 2 diabetes mellitus, age < 75 years; previous oral SU as monotherapy or
in combination with metformin or acarbose; BMI < 35 kg/m²; HbA1c 7.5 - 10.5%; FPG =< 6.7mmol/L
EXCLUSIONCRITERIA: pregnancy or breast-feeding; pre-treatment with insulin or any investigational
drugs within the previous 3 months; clinically relevant somatic or mental diseases
DIAGNOSTIC CRITERIA: ?
Interventions NUMBER OF STUDY CENTRES:
111
COUNTRY/ LOCATION:
Europe
SETTING:
?
INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):
I1:glargine once daily subcutaneously in the morning + 3 mg glimepiride
I2: glargine once daily subcutaneously at bedtime + 3 mg glimepiride
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY):
NPH once daily subcutaneously at bedtime + 3 mg glimepiride
TREATMENT BEFORE STUDY:
SU as monotherapy or in combination with metformin or acarbose
TITRATION PERIOD: complete treatment phase; pre-specified algorithm;
Outcomes PRIMARY OUTCOMES: change of HbA1c from baseline to end point; frequency of patients who
experienced hypoglycaemic events
SECONDARY OUTCOMES: HbA1c <= 7.5%; FPG <= 5.6mmol/L; response rates; mean 24-hour
blood glucose values
ADDITIONAL PUBLISHED OUTCOMES. insulin doses; adverse events; body weight
TIMING OF OUTCOME MEASURES: 24 weeks
Notes STATED AIM OF STUDY: to investigate the efficacy and safety of a combination therapy of SU with
either morning or bedtime insulin glargine in patients with diabetes mellitus type 2 whose diabetes was
poorly controlled with oral antidiabetic drugs
Risk of bias
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Fritsche 2003 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Haak 2005
Methods DURATION OF INTERVENTION: 26 weeks
RUN-IN PERIOD: N, 3 weeks screening period
LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED: patients with type 2 diabetes mellitus
INCLUSION CRITERIA: type 2 diabetes mellitus >= 12 months, age >= 35 years; insulin treatment for
at least 2 months (basal insulin dose >= 30% of the total daily insulin dose); HbA1c <= 12%
EXCLUSION CRITERIA: pregnancy or breast-feeding; OADs within the previous 2 months; prolifer-
ative retinopathy; uncontrolled hypertension; recurrent major hypoglycaemia; impaired renal or hepatic
function; cardiac problems; daily basal insulin dose > 100 IU/day;
DIAGNOSTIC CRITERIA: ?
Interventions NUMBER OF STUDY CENTRES: 63
COUNTRY/ LOCATION: Europe SETTING: ?
INTERVENTION (ROUTE,TOTALDOSE/DAY, FREQUENCY): detemir once daily subcutaneously
at bedtime or detemir twice daily in the morning and at bedtime + mealtime insulin aspart
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH once daily subcutaneously at bed-
time or NPH twice daily in the morning and at bedtime + mealtime insulin aspart
TREATMENT BEFORE STUDY: insulin
TITRATION PERIOD: complete treatment phase; aiming for blood glucose targets pre-breakfast, post-
prandial and nocturnal
Outcomes PRIMARY OUTCOMES: HbA1c after 26 weeks of treatment SECONDARY
OUTCOMES: not specified
ADDITIONAL PUBLISHED OUTCOMES. FPG; self measured blood glucose profiles; within subject
variation of FBG; insulin doses; percentage of patients experiencing a hypoglycaemic episode (overall,
severe and nocturnal); body weight; adverse events; safety
TIMING OF OUTCOME MEASURES: 26 weeks
Notes STATEDAIMOFSTUDY: efficacy and safety comparison of insulin detemir andNPH insulin in patients
with type 2 diabetes on a basal-bolus regimen
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Hermansen 2006
Methods DURATION OF INTERVENTION: 24 weeks
RUN-IN PERIOD: N LANGUAGE OF
PUBLICATION: English
Participants WHO PARTCIPATED: insulin-naive people with type 2 diabetes mellitus
INCLUSIONCRITERIA: insulin-naive people; age >=18 yrs; BMI <= 35 kg/m²; A1c of 7.5% to 10.0%;
type 2 diabetes mellitus for at least 12 months; inadequate control required at least 4 months treatment
with one or two OADs at doses at least half the recommended maximum or highest tolerated
EXCLUSION CRITERIA: use of thiazolidinediones; secondary diabetes, maturity-onset diabetes of the
young; proliferate retinopathy / maculopathy requiring treatment, hypoglycaemia unawareness or recur-
rent major hypoglycaemia, use of drugs affecting glycaemia, impaired hepatic or renal function; significant
cardiovascular disease. pregnancy, breast feeding
DIAGNOSTIC CRITERIA: nr
Interventions NUMBER OF STUDY CENTRES: 58
COUNTRY/ LOCATION: 10 countries of the European Union
SETTING: nr
INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY): detemir (subcutaneous, individu-
ally titrated, twice daily) plus OAD (metformin, insulin secretagogues, alpha-glucosidase inhibitors) (oral,
dose unclear- remained unchanged during treatment period, frequency unclear)
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH (subcutaneous, individually
titrated, twice daily) plus OAD (metformin, insulin secretagogues, alpha-glucosidase inhibitors) (oral,
dose unclear- remained unchanged during treatment period, frequency unclear)
TREATMENT BEFORE STUDY: one or two OADs (metformin, insulin secretagogues, alpha-glucosi-
dase inhibitors) at doses at least half the recommended maximum or highest tolerated
TITRATION PERIOD: 24 weeks
Outcomes PRIMARY OUTCOMES: A1c
SECONDARY OUTCOMES: fasting plasma glucose (FPG); proportion of participants achieving A1c
=< 7.0%; proportion of participants achieving target A1c value without hypoglycaemia (hypoglycaemia
defined as symptomatic episodes confirmed by a plasma glucose value < 72 mg/dL or any single plasma
glucose value < 56 mg/dL); within-participant variation in self-measured pre-breakfast and pre-dinner
plasma glucose; self-measured 10-point plasma glucose profile; adverse events
ADDITIONAL PUBLISHED OUTCOMES: N
TIMING OF OUTCOME MEASURES: 24 weeks
Notes STATED AIM OF STUDY: To assess efficacy and tolerability of insulin detemir or NPH insulin added
to oral therapy for type 2 diabetes in a treat-to-target titration protocol
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Massi 2003
Methods DURATION OF INTERVENTION: 52 weeks
RUN-IN PERIOD: N, during a 4 week screening phase the patients continued their previous oral
antidiabetic treatment, and were familiarised with the insulin delivery device and blood glucose meter
LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED: patients with type 2 diabetes mellitus
INCLUSION CRITERIA: diabetes duration of at least 3 years; men or women; age 40 - 80 years; oral
therapy with SU alone or in combination with acarbose, metformin, or metformin alone, or insulin once
daily plus oral antihyperglycaemic drugs for => 1 year; BMI < 40 kg/m2; HbA1c 7.5 to 12.0%; negative
history of ketoacidosis;
EXCLUSION CRITERIA: regular insulin therapy during the last four weeks before screening; diabetic
retinopathy with surgical treatment in the 3 months before study entry or requiring treatment within
3 months of study entry; night shift worker; treatment with any investigational drugs in the last 2
months before study entry; clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other
major systemic diseases that would make implementation of the study protocol or interpretation of the
study results difficult; drug or alcohol abuse; likelihood of requiring treatment during the study period
with drugs not permitted by the protocol; impaired hepatic function as shown by but not limited to
alanine aminotransferase or aspartate aminotransferase greater than twice the upper limit measured at
visit one; impaired renal function as shown by but not limited to serum creatinine > 1.5 mg/dL; mental
condition rendering the subject unable to understand the nature, scope, and possible consequences of the
study; evidence of an uncooperative attitude; inability to attend follow up visits
DIAGNOSTIC CRITERIA: ?
Interventions NUMBER OF STUDY CENTRES: 57
COUNTRY/ LOCATION: Europe, South Africa
SETTING: ?
INTERVENTION (ROUTE,TOTALDOSE/DAY, FREQUENCY): glargine once daily subcutaneously
at bedtime + previous oral antihyperglycaemic agents continued
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH once daily subcutaneously at bed-
time + previous oral antihyperglycaemic agents continued
TREATMENT BEFORE STUDY: oral therapy with SU alone or in combination with acarbose, met-
formin, or metformin alone, or insulin once daily plus oral antihyperglycaemic drugs
TITRATION PERIOD: as needed according to self monitored FPG (optimal dose was defined by an
FPG target of 6.66 mol/L over at least 2-4 days without nocturnal hypoglycaemia)
Outcomes PRIMARY OUTCOME Change in HbA1c from baseline to endpoint
SECONDARY OUTCOME FPG; FBG; FBG variability; 24 hour blood glucose;
ADDITIONAL PUBLISHED OUTCOMES. hypoglycaemia: symptomatic, severe, nocturnal; adverse
events; E. coli and insulin antibodies; insulin dose; body weight; safety parameters TIMING OF
PUBLISHED OUTCOMES: 52 weeks
Notes STATEDAIMOFSTUDY: to compare the effects of insulin glargine andNPHhuman insulin on glycated
haemoglobin values, fasting plasma glucose and FBG levels, the blood glucose profile, hypoglycaemia, and
safety for a treatment period of 52 weeks in patients with Type 2 diabetes. In regard to in- and exclusion
criteria information from the present paper are scarce. Most of the information is available only from
the paper by H. Yki-Järvinen which reports on the insulin naive subgroup. According to the FDA report
and the publication by Yki-Järvinen eye examinations and fundoscopy were done. No results concerning
retinopathy are presented in the papers at hand
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Massi 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Riddle 2003
Methods DURATION OF INTERVENTION: 24 weeks
RUN-IN PERIOD: 4 weeks; treatment ?
LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED: patients with type 2 diabetes mellitus
INCLUSION CRITERIA: men or women; age 30 to 70 years; stable dose of one or two oral antihyper-
glycaemic agents (SU, metformin, glitazone) for >= 3 months; BMI 26 to 40 kg/m2; HbA1c 7.5% to 10.
0%; FPG >= 7.8 mmol/L
EXCLUSION CRITERIA: prior use of insulin (except for gestational diabetes < 1 week); current use of
alpha-glucosidase inhibitor or rapid-acting insulin secretagogues; use of other agents affecting glycaemic
control; history of ketoacidosis or inability to recognise hypoglycaemia; history of drug or alcohol abuse;
serum alanine or aspartate aminotransferase more than twofold above upper limit; serum creatinine => 1,
5mg/dL (m) or 1,4mg/dL (f ); positive test for GAD antibody; fasting plasma C-peptide <= 0.25 pmol/
mL
DIAGNOSTIC CRITERIA: ?
Interventions NUMBER OF STUDY CENTRES: 80
COUNTRY/ LOCATION: US, Canada
SETTING: ?
INTERVENTION (ROUTE,TOTALDOSE/DAY, FREQUENCY): glargine once daily subcutaneously
at bedtime + oral antihyperglycaemic agents (SU, metformin, glitazones) continued at pre-study dosages
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH once daily subcutaneously at bed-
time + oral antihyperglycaemic agents (SU, metformin, glitazones) continued at pre-study dosages
TREATMENT BEFORE STUDY: one or two oral antihyperglycaemic agents (SU, metformin, piogli-
tazone, rosiglitazone)
TITRATION PERIOD: as needed to achieve target FPG <= 5.6 mmol/L (predefined algorithm)
Outcomes PRIMARY OUTCOME
percentage of subjects achieving HbA1c <= 7.0% without a single instance of symptomatic nocturnal
hypoglycaemia confirmed by plasma-referenced glucose <= 4 mmol/L or meeting criteria for severe hy-
poglycaemia or both
SECONDARY OUTCOME
changes from baseline for HbA1c, FPG and weight; percentage of subjects achieving HbA1c <= 7.0%
or FPG <= 5.6 mmolL independent of occurrence of hypoglycaemia; subjects achieving FPG <= 5.6
mmol/L without confirmed hypoglycaemia; with-in subject variability between seven sequential fasting
glucose measures; rates of symptomatic hypoglycaemia including unconfirmed, confirmed and severe
hypoglycaemia;
ADDITIONAL PUBLISHED OUTCOMES.
N
TIMING OF PUBLISHED OUTCOMES:
25Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Riddle 2003 (Continued)
24 weeks
Notes STATED AIMOF STUDY: to compare the abilities of glargine and NPH to reduce HbA1c to 7% when
added to ongoing oral therapy and the hypoglycaemia accompanying this effort using a simple algorithm
for insulin dosage titration seeking a FPG target of 5.6 mmol/L
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Rosenstock 2001
Methods DURATION OF INTERVENTION: 28 weeks
RUN-IN PERIOD: N LANGUAGE OF
PUBLICATION: English
Participants WHO PARTCIPATED: patients with type 2 diabetes mellitus
INCLUSION CRITERIA: men or women; age 40 to 80 years; insulin treatment for >= 3 months; BMI
< 40 kg/m2; HbA1c 7.0 to 12.0%;
EXCLUSION CRITERIA: OAD treatment within 3 months prior to study inclusion; history of drug or
alcohol abuse; significant hepatic or renal impairment
DIAGNOSTIC CRITERIA: ?
Interventions NUMBER OF STUDY CENTRES: 59
COUNTRY/ LOCATION: North America
SETTING: ?
INTERVENTION (ROUTE,TOTALDOSE/DAY, FREQUENCY): glargine once daily subcutaneously
at bedtime + pre-meal regular insulin
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH once at bedtime or twice daily in
the morning or at bedtime subcutaneously + pre-meal regular insulin
TREATMENT BEFORE STUDY: insulin
TITRATION PERIOD: as needed to achieve target FPG 4.4 to 7.8 mmol/L (the evening dose of the
basal insulin was increased if FPG was >= 10mmol/L on three consecutive measurements unless nocturnal
hypoglycaemia occurred; pre-meal insulin target: pre-meal blood glucose 4.4 to 7.8 mmol/L and bedtime
blood glucose 6.7 to 10.0 mmol/L
Outcomes PRIMARY OUTCOME: change of HbA1c from baseline to end point
SECONDARY OUTCOME: changes from baseline for FBG at weeks 8, 20, 28, and at study end point
(mean self monitored blood glucose values on 7 consecutive days before study visits); hypoglycaemia
ADDITIONAL PUBLISHEDOUTCOMES: insulin doses; adverse events; insulin antibody levels; body
weight TIMING OF
PUBLISHED OUTCOMES: 28 weeks
Notes STATED AIM OF STUDY: to compare the safety and effectiveness of once daily insulin glargine with
once or twice daily NPH insulin in patients who were not taking oral agents and who had previously
received basal insulin with or without regular insulin for postprandial glycaemic control According to the
EMEA report :“...additional antidiabetic treatment was provided by oral antidiabetic drugs.”
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Rosenstock 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Yki-Järvinen 2006
Methods DURATION OF INTERVENTION: 36 weeks
RUN-IN PERIOD: 4 weeks
LANGUAGE OF PUBLICATION: English
Participants WHO PARTCIPATED: poorly controlled type 2 diabetes patients on oral hypoglycaemic agents
INCLUSION CRITERIA: male or female; age 35 to 75 years; type 2 diabetes mellitus; had been treated
with a stable dose of sulfonylurea (any dose) and metformin (>= 1.5 g) or with metformin alone for at
least 3 months; BMI 20 to 40 kg/m2; HbA1c >= 8.0%; mean fasting plasma glucose >= 7 mmol/L (daily
home glucose monitoring); fasting C-peptide >= 0.33 nmol/L (reference range 0.33 to 0.69 nmol/L)
EXCLUSION CRITERIA: other oral antihyperglycaemic agents; prior use of insulin; positive GAD
antibodies; history of ketoacidosis; non-compliance with regard to daily measurements of FPG in the run
in phase, abnormal safety laboratory tests; current or past history of alcohol or drug abuse; night shift-
work; pregnancy; treatment with any investigational drug in the past 2 month prior start of trial; use of
drugs likely to interfere with glucose control; clinically relevant major systemic disease other than diabetes;
diabetic retinopathy requiring surgical (laser or other) treatment in the 3 months before or during the
study
DIAGNOSTIC CRITERIA: nr
Interventions NUMBER OF STUDY CENTRES: 7
COUNTRY/ LOCATION: Six sites in Finland, one in UK
SETTING: nr
INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY): glargine (subcutaneous, individ-
ually titrated, once at bedtime) plus metformin (oral, dose unclear [abstract 2 g], frequency unclear)
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH (subcutaneous, individually, once
at bedtime) plus metformin (oral, dose unclear [abstract 2 g], frequency unclear)
TREATMENT BEFORE STUDY: oral antihyperglycaemic agents: sulfonylurea and metformin or met-
formin alone; with a stable dose
TITRATION PERIOD: nr
Outcomes PRIMARY OUTCOMES: Change in HbA1c from baseline to end of study
SECONDARY OUTCOMES: diurnal glucose concentrations; symptomatic hypoglycaemia; weight; S-
ALT; triglycerides; insulin doses between groups
ADDITIONAL PUBLISHED OUTCOMES. fasting plasma glucose, adverse events
TIMING OF OUTCOME MEASURES: 36 weeks
Notes STATED AIM OF STUDY: To compare the combination therapy insulin glargine plus metformin with
NPH insulin plus metformin
Risk of bias
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Yki-Järvinen 2006 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Yokoyama 2006
Methods DURATION OF INTERVENTION:
6 months
RUN-IN PERIOD:
3 months
LANGUAGE OF PUBLICATION:
English
Participants WHO PARTCIPATED: intensively treated type 2 diabetes patients
INCLUSION CRITERIA: type 2 diabetes mellitus; 2 years duration of diabetes mellitus; age >= 35;
negative GAD test; without any episodes of ketoacidosis; BMI <= 40 kg/m²; HbA1c <= 10%; patients
had once poor glycaemic control (HbA1c ? 8%) despite optimal dose of sulfonylureas in addition to diet
and exercise; for more than 1 year on basal/prandial insulin therapy using aspart / lispro at each meal and
NPH at bedtime with or without any anti-diabetic oral agents
EXCLUSION CRITERIA: impaired hepatic, renal or cardiac function; recurrent major hypoglycaemia
DIAGNOSTIC CRITERIA: nr
Interventions NUMBER OF STUDY CENTRES: 1
COUNTRY/ LOCATION: Japan
SETTING: outpatient clinic
INTERVENTION(ROUTE,TOTALDOSE/DAY, FREQUENCY): glargine at breakfast, subcutaneous
(total dose should be 50% of the total daily insulin dose, once) plus mealtime aspart / lispro subcutaneous,
(individually titrated, at eachmeal); additional treatment with oral antihyperglycaemic agents was possible
(oral, dose unclear, frequency unclear)
CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): NPH at bedtime, subcutaneous plus
mealtime aspart / lispro, subcutaneous, (individually titrated, at each meal); additional treatment with
oral antihyperglycaemic agents was possible (oral, dose unclear, frequency unclear)
TREATMENTBEFORE STUDY: sulfonylureas in addition to diet and exercise then having been treated
for more than a year with basal-prandial insulin therapy using aspart / lispro at each meal and NPH at
bedtime with or without OADs
TITRATION PERIOD: nr
Outcomes PRIMARY OUTCOMES: HbA1c (not specified in publication)
SECONDARY OUTCOMES: total daily insulin dose; fasting and postprandial blood glucose; BMI;
hypoglycaemia
ADDITIONAL PUBLISHED OUTCOMES: NA
TIMING OF OUTCOME MEASURES: 6 months
Notes STATED AIM OF STUDY: To investigate if increasing the dose of morning glargine up to half the total
insulin requirement may lead to better glycaemic control
Risk of bias
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Yokoyama 2006 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
OAD: oral antihyperglycaemic drug; ?: unclear; GAD: glutamic acid decarboxylase; FBG: fasting blood glucose; nr: not reported;
DTSQc: Diabetes Treatment Satisfaction Questionaire; SU: sulfonylurea; FP(B)G: fasting plasma (blood) glucose; N: no, BMI:
body mass index; FDA: Food and Drug Administration; S-ALT: serum alanin aminotrasferase; EMEA: europeanMedicines Agency;
na: not applicable
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cada 2005 not a randomised controlled trial
Garber 2003 not a randomised controlled trial
Kacerovsky-Bielesz extension study of Massi 2003 under non-randomised conditions
Kaplan 2004 no patients with type 2 diabetes
Krankenpflege 2004 different antihyperglycaemic co-therapy in the treatment arms
Nakhmanovich 2001 not a randomised controlled trial
Riddle 2006 not a randomised controlled trial
Stoneking 2005 not a randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Kawamori 2003
Methods Through communication with Sanofi-Aventis we became aware of one additional study comparing insulin glargine
with NPH insulin in patients with type 2 diabetes mellitus (Kawamori 2003), which was not listed in any of the
electronic databases searched. Unfortunately, the publication was not available in time for inclusion in this review.
We therefore will assess its relevance in the next update of this review
Participants
Interventions
Outcomes
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Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Hypoglycaemia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe hypoglycaemia - Glargine
vs. NPH
4 2207 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.40, 1.23]
2 Severe hypoglycaemia - Detemir
vs. NPH
2 980 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.50 [0.18, 1.38]
3 Symptomatic hypoglycaemia -
Glargine vs. NPH
3 1458 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.75, 0.95]
4 Overall hypoglycaemia -
Detemir vs. NPH
2 980 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.74, 0.90]
5 Nocturnal hypoglycaemia -
Glargine vs. NPH
3 1458 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.55, 0.80]
6 Nocturnal hypoglycaemia -
Detemir vs. NPH
2 980 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.52, 0.76]
Comparison 2. HbA1c
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in HbA1c - Glargine vs.
NPH
4 1568 Mean Difference (IV, Random, 95% CI) 0.05 [-0.08, 0.17]
2 Change in HbA1c (pooled SD) -
Glargine vs. NPH
6 2902 Mean Difference (IV, Random, 95% CI) -0.00 [-0.10, 0.09]
3 Change in HbA1c - Detemir vs.
NPH
2 967 Mean Difference (IV, Random, 95% CI) 0.12 [0.01, 0.23]
4 Change in HbA1c (pooled SD) -
Detemir vs. NPH
2 967 Mean Difference (IV, Random, 95% CI) 0.15 [-0.02, 0.32]
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Analysis 1.1. Comparison 1 Hypoglycaemia, Outcome 1 Severe hypoglycaemia - Glargine vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 1 Severe hypoglycaemia - Glargine vs. NPH
Study or subgroup Glargine NPH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fritsche 2003 4/227 6/232 20.1 % 0.68 [ 0.19, 2.38 ]
Riddle 2003 9/360 7/389 32.1 % 1.40 [ 0.52, 3.76 ]
Rosenstock 2001 1/259 6/259 14.2 % 0.24 [ 0.05, 1.05 ]
Eliaschewitz 2006 6/231 11/250 33.6 % 0.59 [ 0.22, 1.55 ]
Total (95% CI) 1077 1130 100.0 % 0.70 [ 0.40, 1.23 ]
Total events: 20 (Glargine), 30 (NPH)
Heterogeneity: Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Glargine Favours NPH
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Analysis 1.2. Comparison 1 Hypoglycaemia, Outcome 2 Severe hypoglycaemia - Detemir vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 2 Severe hypoglycaemia - Detemir vs. NPH
Study or subgroup Detemir NPH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Haak 2005 6/341 3/164 52.9 % 0.96 [ 0.24, 3.92 ]
Hermansen 2006 1/237 6/238 47.1 % 0.24 [ 0.05, 1.05 ]
Total (95% CI) 578 402 100.0 % 0.50 [ 0.18, 1.38 ]
Total events: 7 (Detemir), 9 (NPH)
Heterogeneity: Chi2 = 1.80, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Detemir Favours NPH
Analysis 1.3. Comparison 1 Hypoglycaemia, Outcome 3 Symptomatic hypoglycaemia - Glargine vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 3 Symptomatic hypoglycaemia - Glargine vs. NPH
Study or subgroup Glargine NPH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rosenstock 2001 159/259 173/259 40.0 % 0.92 [ 0.81, 1.05 ]
Fritsche 2003 98/227 135/232 26.8 % 0.74 [ 0.62, 0.89 ]
Eliaschewitz 2006 122/231 157/250 33.2 % 0.84 [ 0.72, 0.98 ]
Total (95% CI) 717 741 100.0 % 0.84 [ 0.75, 0.95 ]
Total events: 379 (Glargine), 465 (NPH)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 2.82 (P = 0.0048)
0.2 0.5 1 2 5
Favours Glargine Favours NPH
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Analysis 1.4. Comparison 1 Hypoglycaemia, Outcome 4 Overall hypoglycaemia - Detemir vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 4 Overall hypoglycaemia - Detemir vs. NPH
Study or subgroup Detemir NPH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Haak 2005 171/341 95/164 31.9 % 0.87 [ 0.73, 1.02 ]
Hermansen 2006 151/237 191/238 68.1 % 0.79 [ 0.71, 0.89 ]
Total (95% CI) 578 402 100.0 % 0.82 [ 0.74, 0.90 ]
Total events: 322 (Detemir), 286 (NPH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
0.2 0.5 1 2 5
Favours Detemir Favours NPH
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Analysis 1.5. Comparison 1 Hypoglycaemia, Outcome 5 Nocturnal hypoglycaemia - Glargine vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 5 Nocturnal hypoglycaemia - Glargine vs. NPH
Study or subgroup Glargine NPH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fritsche 2003 52/227 89/232 30.9 % 0.60 [ 0.45, 0.80 ]
Rosenstock 2001 81/259 104/259 40.6 % 0.78 [ 0.62, 0.98 ]
Eliaschewitz 2006 47/231 87/250 28.5 % 0.58 [ 0.43, 0.79 ]
Total (95% CI) 717 741 100.0 % 0.66 [ 0.55, 0.80 ]
Total events: 180 (Glargine), 280 (NPH)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.98, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 4.20 (P = 0.000026)
0.2 0.5 1 2 5
Favours Glargine Favours NPH
Analysis 1.6. Comparison 1 Hypoglycaemia, Outcome 6 Nocturnal hypoglycaemia - Detemir vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 1 Hypoglycaemia
Outcome: 6 Nocturnal hypoglycaemia - Detemir vs. NPH
Study or subgroup Detemir NPH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Haak 2005 59/341 46/164 33.0 % 0.62 [ 0.44, 0.86 ]
Hermansen 2006 71/237 112/238 67.0 % 0.64 [ 0.50, 0.81 ]
Total (95% CI) 578 402 100.0 % 0.63 [ 0.52, 0.76 ]
Total events: 130 (Detemir), 158 (NPH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
0.2 0.5 1 2 5
Favours Detemir Favours NPH
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Analysis 2.1. Comparison 2 HbA1c, Outcome 1 Change in HbA1c - Glargine vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 2 HbA1c
Outcome: 1 Change in HbA1c - Glargine vs. NPH
Study or subgroup Glargine NPH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rosenstock 2001 259 -0.41 (1.61) 259 -0.59 (1.61) 21.8 % 0.18 [ -0.10, 0.46 ]
Fritsche 2003 227 -0.96 (1.32) 232 -0.84 (1.34) 28.3 % -0.12 [ -0.36, 0.12 ]
Eliaschewitz 2006 231 -1.38 (1.32) 250 -1.44 (1.33) 29.9 % 0.06 [ -0.18, 0.30 ]
Yki-Ja¨rvinen 2006 61 -1.99 (0.85) 49 -2.1 (0.7) 20.0 % 0.11 [ -0.18, 0.40 ]
Total (95% CI) 778 790 100.0 % 0.05 [ -0.08, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
-1 -0.5 0 0.5 1
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Analysis 2.2. Comparison 2 HbA1c, Outcome 2 Change in HbA1c (pooled SD) - Glargine vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 2 HbA1c
Outcome: 2 Change in HbA1c (pooled SD) - Glargine vs. NPH
Study or subgroup Glargine NPH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rosenstock 2001 259 -0.41 (1.3) 259 -0.59 (1.3) 17.9 % 0.18 [ -0.04, 0.40 ]
Fritsche 2003 227 -0.96 (1.3) 232 -0.84 (1.3) 15.8 % -0.12 [ -0.36, 0.12 ]
Eliaschewitz 2006 231 -1.38 (1.3) 250 -1.44 (1.3) 16.6 % 0.06 [ -0.17, 0.29 ]
Yki-Ja¨rvinen 2006 61 -1.99 (1.3) 49 -2.1 (1.3) 3.7 % 0.11 [ -0.38, 0.60 ]
Riddle 2003 372 -1.65 (1.3) 392 -1.59 (1.3) 26.3 % -0.06 [ -0.24, 0.12 ]
Massi 2003 289 -0.46 (1.3) 281 -0.38 (1.3) 19.7 % -0.08 [ -0.29, 0.13 ]
Total (95% CI) 1439 1463 100.0 % 0.00 [ -0.10, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.85, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
-1 -0.5 0 0.5 1
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Analysis 2.3. Comparison 2 HbA1c, Outcome 3 Change in HbA1c - Detemir vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 2 HbA1c
Outcome: 3 Change in HbA1c - Detemir vs. NPH
Study or subgroup Detemir NPH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Haak 2005 341 -0.2 (1.27) 164 -0.4 (1.28) 20.6 % 0.20 [ -0.04, 0.44 ]
Hermansen 2006 230 -1.81 (0.67) 232 -1.91 (0.66) 79.4 % 0.10 [ -0.02, 0.22 ]
Total (95% CI) 571 396 100.0 % 0.12 [ 0.01, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
-1 -0.5 0 0.5 1
Favours Detemir Favours NPH
Analysis 2.4. Comparison 2 HbA1c, Outcome 4 Change in HbA1c (pooled SD) - Detemir vs. NPH.
Review: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Comparison: 2 HbA1c
Outcome: 4 Change in HbA1c (pooled SD) - Detemir vs. NPH
Study or subgroup Detemir NPH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Haak 2005 341 -0.2 (1.3) 164 -0.4 (1.3) 48.9 % 0.20 [ -0.04, 0.44 ]
Hermansen 2006 230 -1.81 (1.3) 232 -1.91 (1.3) 51.1 % 0.10 [ -0.14, 0.34 ]
Total (95% CI) 571 396 100.0 % 0.15 [ -0.02, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
-1 -0.5 0 0.5 1
Favours Detemir Favours NPH
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A D D I T I O N A L T A B L E S
Table 1. Definition of hypoglycaemia in study or as reported
Hypogly-
caemia
Eliasche-
witz
2006
Fritsche,
2003
Haak,
2005
Her-
mansen
2006
Massi,
2003
Riddle,
2003
Rosen-
stock,
2001
Yki-
Järvinen
2006
Bias
severe require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 2.8
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
symp-
toms and
require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 2.8
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
require-
ment of as-
sis-
tance from
another
person
require-
ment of as-
sis-
tance from
another
person
symp-
toms and
require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 2.8
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
symp-
toms and
require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 3.1
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
symp-
toms and
require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 2.0
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
symp-
toms and
require-
ment of as-
sis-
tance from
another
person and
blood glu-
cose < 3.1
mmol/L or
prompt re-
covery af-
ter oral car-
bohydrate,
i.v. glucose
or
glucagon
adminis-
tration
possible
symp-
tomatic
symptoms
or
blood glu-
cose mea-
surement
or both
symptoms
or
blood glu-
cose mea-
surement
or both
- - symptoms
or
blood glu-
cose mea-
surement
or both
symptoms
or
blood glu-
cose mea-
surement
or both
symptoms
or
blood glu-
cose mea-
surement
or both
symptoms
or
blood glu-
cose mea-
surement
or both
possible
overall - - symptoms
or
blood glu-
cose mea-
surement
or
blood glu-
cose < 2.8
mmol/L or
both
- - - - possible /
unclear
nocturnal while
asleep be-
tween bed-
time
and getting
while
asleep, be-
tween bed-
time after
the
23:00 - 06:
00
23:00 - 06:
00
while
asleep, be-
tween the
in-
sulin injec-
between
the in-
sulin injec-
tion in the
evening
while
asleep, be-
tween the
in-
sulin injec-
- possible
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Table 1. Definition of hypoglycaemia in study or as reported (Continued)
up in the
morning
evening in-
jection and
before
the patient
awakes in
the morn-
ing
tion in the
evening
and before
the insulin
in-
jection in
the morn-
ing or be-
fore blood
glucose
measure-
ment in
the morn-
ing
and break-
fast
or OAD in
the morn-
ing
tion in the
evening
and the in-
sulin injec-
tion or
blood glu-
cose mea-
surement
in the
morning
Notes
OAD: oral
antidia-
betic drugs
A P P E N D I C E S
Appendix 1. Search strategy
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw =
text word; pt = publication type; sh = MeSH; adj = adjacent
1. glargin$.ti,ab,ot,tn,sh.
2. (Gly$A21 or A21Gly$ or (gly$ adj1 A21)).ti,ab,ot.
3. (Arg$B31 or B31Arg$ or (arg$ adj1 B31)).ti,ab,ot.
4. (Arg$B32 or B32Arg$ or (arg$ adj1 B32)).ti,ab,ot.
5. (HOE-901 or HOE901).ti,ab,ot,tn.
6. Lantus$.ti,ab,ot,tn.
7. (glargin$ or 160337-95-1).rn.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. detemir$.ti,ab,ot,tn,sh.
10. (Lys$B29 or B29Lys$ or (lys$ adj1 B29)).ti,ab,ot.
11. (Ala$B30 or B30Ala$ or (ala$ adj1 B30)).ti,ab,ot.
12. (NN-304 or NN304).ti,ab,ot,tn.
13. Levemir$.ti,ab,ot,tn.
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(Continued)
14. (detemir$ or 169148-63-4 or 201305-44-4 or 270588-25-5).rn.
15. 9 or 10 or 11 or 12 or 13 or 14
16. 8 or 15
17. (insulin$ adj6 (analog$ or derivat$)).ti,ab,ot.
18. (longacting adj6 insulin$).ti,ab,ot.
19. ((long$ or delayed$ or slow$ or ultralong$) adj1 (acting or action) adj6 insulin$).ti,ab,ot.
20. ((novel or new) adj6 insulin$).ti,ab,ot.
21. 17 or 18 or 19 or 20
22. exp insulin/aa
23. exp Insulin Derivative/
24. 22 or 23
25. 21 or 24
26. exp Diabetes Mellitus/
27. diabet$.ti,ab,ot.
28. mellitu$.ti,ab,ot.
29. IDDM.ti,ab,ot.
30. MODY.ti,ab,ot.
31. NIDDM.ti,ab,ot.
32. (T1DM or T2DM or ((T1 or T2) adj1 DM)).ti,ab,ot.
33. (insulin$ depend$ or insulin?depend$ or noninsulin$ or noninsulin?depend$).ti,ab,ot.
34. ((matury or late) adj onset$ adj6 diabet$).ti,ab,ot.
35. (typ$ adj6 diabet$).ti,ab,ot.
36. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
37. exp Diabetes Insipidus/
38. insipid$.ti,ab,ot.
39. 37 or 38
40. 26 or 36
41. 40 or (27 not (39 not 40))
42. controlled clinical trial.pt.
43. controlled clinical trials/
44. randomized controlled trial.pt.
45. randomized controlled trials/
46. random allocation/
47. cross-over studies/
48. double-blind method/
49. single-blind method/
50. 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49
51. ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).ti,ab,ot.
52. ((random$ or cross-over or crossover) adj25 (trial$ or study or studies or intervention$ or investigat$ or experiment$ or design$
or method$ or group$ or evaluation or evidenc$ or data or test$ or condition$)).ti,ab,ot.
53. (random$ adj25 (cross over or crossover)).ti,ab,ot.
54. 51 or 52 or 53
55. 50 or 54
56. exp meta-analysis/
57. meta analysis.pt.
58. (metaanaly$ or meta analy$).ti,ab,ot.
59. 56 or 57 or 58
60. exp biomedical technology assessment/
61. hta.ti,ab,ot.
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(Continued)
62. ((biomed$ or health$) adj6 technolog$ adj6 assessment$).ti,ab,ot.
63. 60 or 61 or 62
64. exp “Review Literature”/
65. ((review$ or search$) adj25 (medical databas$ or medline or pubmed or embase or cochrane or systemat$)).ti,ab,ot.
66. 64 or 65
67. addresses.pt.
68. bibliography.pt.
69. biography.pt.
70. “case reports”.pt.
71. “clinical conference”.pt.
72. comment.pt.
73. “conference abstract”.pt.
74. “conference paper”.pt.
75. congresses.pt.
76. “consensus development conference nih”.pt.
77. “consensus development conference”.pt.
78. dictionary.pt.
79. directory.pt.
80. editorial.pt.
81. festschrift.pt.
82. “historical article”.pt.
83. interview.pt.
84. lectures.pt.
85. “legal cases”.pt.
86. legislation.pt.
87. letter.pt.
88. “newspaper article”.pt.
89. note.pt.
90. “patient education handout”.pt.
91. “periodical index”.pt.
92. “review of reported cases”.pt.
93. “technical report”.pt.
94. or/67-93
95. exp Animals/
96. exp animal/
97. exp animals/
98. “animal experiment”.sh.
99. or/95-98
100. exp Humans/
101. exp human/
102. 100 or 101
103. 99 not 102
104. cn$.an.
105. (16 or 25) and 41
106. 55 not (94 or 103)
107. 59 or 63 or 66
108. 105 and (106 or 104)
109. 105 and 107
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(Continued)
There were no language restrictions.
Appendix 2. Baseline characteristics
Charac-
teristic
Eliasche-
witz
2006
Fritsche
2003
Haak
2005
Her-
mansen
2006
Massi
2003
Riddle
2003
Rosen-
stock
2001
Yki-
Järvinen
2006
Yokoyama
2006
Inter-
vention 1
(I1) Inter-
vention 2
(I2) Con-
trol 1 (C1)
I1: subcu-
taneous 1
x glargine
at bedtime
plus 4
mg/day
glimepiride
in the
morning
C1: sub-
cutaneous
1 x NPH
at bedtime
plus 4
mg/day
glimepiride
in the
morning
I1:
glargine
in the
morning
+ 3 mg
glimepiride
I2:
glargine at
bedtime
+ 3 mg
glimepiride
C1: NPH
at bedtime
+ 3 mg
glimepiride
I1: detemir
once daily
subcuta-
neously
at bedtime
or detemir
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
C1: NPH
once daily
subcuta-
neously at
bedtime or
NPH
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
I1: detemir
in the
morning
and in the
evening
(within 1 h
before din-
ner
until bed-
time) plus
OADs (not
titrated)
C1: NPH
in the
morning
and in the
evening
(within 1 h
before din-
ner
until bed-
time) plus
OADs (not
titrated)
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
vious oral
antihyper-
glycaemic
agents
continued
C1: NPH
once daily
subcuta-
neously at
bed-
time + pre-
vious oral
antihyper-
glycaemic
agents
continued
I1: sub-
cutaneous
glargine
once at
bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
C1: sub-
cutaneous
NPH once
at bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
meal regu-
lar insulin
C1: NPH
once at
bedtime or
twice daily
in
the morn-
ing and
at bedtime
subcuta-
neously
+ premeal
regular in-
sulin
I1:
glargine
once
at bedtime
plus met-
formin
C1:
NPH once
at bedtime
plus met-
formin
I1:
glargine in
the morn-
ing plus as-
part
/ lispro at
each
meal with
or without
OADs
C1: NPH
at bedtime
plus aspart
/ lispro at
each
meal with
or without
OADs
[n] (I1/ I2 /
C1 / total)
I1: 231
C1: 250
I1: 237
I2: 229
C1: 234
total: 700
I1: 341
C1: 164
total: 505
I1: 237
C1: 238
I1: 293
C1:285
Total: 578
I1: 372
C1: 392
Total: 764
I1: 259
C1: 259
Total: 518
I1: 61
C1: 49
I1: 31
C1: 31
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(Continued)
Sex [n,%]
(I1/ I2 /C1
/ total)
I1: 99,
43%
C1: 95,
38%
m - I1: 122
/ I2: 132 /
C1: 119
f - I1: 114
/ I2: 95 /
C1: 113
m - I1: 165
/ C1: 93
f - I1: 176
/ C1: 71
I1: 117,
49%
C1: 135,
57%
m
- I1: 53% /
C1: 54%
f
- I1: 47%/
C1: 46%
m
- I1: 55% /
C1: 56%
f - I1: 45%
/ C1: 44%
m
- I1: 150,
58% / C1:
161, 62%
f - I1: 109,
42% / C1:
98, 38%
I1: 38,
62%
C1: 32,
65%
I1: 15,
48%
C1: 19,
61%
Age, y
[mean,
SD] (I1/ I2
/ C1 /total)
I1: 56 (10)
C: 57 (10)
I1: 61 (9)
I2: 60 (9)
C1: 62 (9)
total: nr
I1: 61 (8.
7)
C1: 60 (8.
4)
total: nr
I1: 61 (9)
C1: 60 (9)
I1: 60 (9.
3)
C1: 59 (9.
1)
total: 60
(9.2)
I1: 55 (9.
5)
C1: 56 (8.
9)
total: nr
I1: 60 (9.
7)
C1: 59 (9.
9)
total: nr
I1: 56 (1
SE)
C1: 57 (1
SE)
I1: 61 (13)
C1: 62
(10)
Eth-
nic groups
(I1/ I2 /C1
/ total)
Caucasian
- I1: 101,
43.7%
/ C1: 121,
48.4%
Black - I1:
12, 5.2% /
C1: 7, 2.
8% Asian/
Oriental -
I1: 3, 1.3%
/ C1: 0, 0.
0%
Multiracial
- I1: 100,
43.3%
/ C1: 108,
43.2%
Hispanic -
I1: 15, 6.
5% / C1:
13, 5.2%
Other - I1:
0, 0.0% /
C1: 1, 0.
4%
nr Cau-
casian - I1:
338 / C1:
162Asian -
I1: 3 / C1:
2
White - I1:
232, 97.
8% / C1:
237, 99.
6% Black -
I1: 1, 0.4%
/ C1: 0, 0.
0%
Asian - I1:
4, 1.7% /
C1: 0, 0.
0%
Other - I1:
0, 0.0% /
C1: 1, 0.
4%
nr Caucasian
- I1: 84% /
C1: 83%
Black - I1:
11% / C1:
13%
Asian - I1:
3% / C1:
3%
Multiracial
- I1: 1% /
C1: 1%
Hispanic
heritage:
I1: 10% /
C1: 6%
Caucasian
- I1: 208,
81% / C1:
209, 81%
Black - I1:
40, 16% /
C1: 36,
14% His-
panic:
I1: 22, 9%
/ C1: 22,
9%
nr nr
Duration
of disease,
y [mean,
SD] (I1/ I2
/ C1 /total)
I1: 10 (6.
4)
C1: 11 (6.
4)
I1: 9 (0-
38)
[range]
I2: 8 (1-
51)
[range]
C1: 9 (1-
I1: 13 (7.
4)
C1: 14 (8.
0)
I1: 10 (6.
6)
C1: 10 (6.
2)
I1: 10 (6.
2)
C1: 11 (6.
0)
I1: 8 (5.6)
C1: 9 (5.6)
I1: 13 (8.
3)
C1: 14 (9.
0)
I1: 9 (1
SE)
C1: 9 (1
SE)
I1: 14 (10)
C1: 12 (9)
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(Continued)
39) [range]
Body mass
index, kg/
m² [mean,
SD] (I1/ I2
/ C1 / to-
tal)
I1: 27.3 (3.
7)
C1: 27.2
(4.0)
I1: 28.6 (4.
5)
I2: 28.7 (3.
9)
C1: 28.9
(3.9)
I1: 30.1 (5.
0)
C1: 31.1
(5.8)
I1: 28.9 (3.
6)
C1: 29.0
(3.6)
I1: 29.3 (4.
3)
C1: 28.8
(4.3)
Total: 29.1
(4.3)
I1: 32.5 (4.
6)
C1: 32.2
(4.8)
I1: 30.7 (5.
0)
C1: 30.4
(5.1)
I1: 31.3 (0.
7 SE)
C1: 32.0
(0.8 SE)
I1: 26.4 (4.
5)
C1: 26.1
(3.2)
Pharmaco-
naive
patients [n,
%] (I1/ I2 /
C1 / total)
I1: 0, 0%
C1: 0, 0%
I1: 0% I2:
0%
C1: 0%
total: 0%
I1: 0%
C1: 0%
total: 0%
I1: 0, 0%
C1: 0, 0%
I1: ?
C1: ?
total: 0.2%
I1: 0%
C1: 0%
total: 0%
I1: 0%
C1: 0%
Total: 0%
I1: 0, 0%
C1: 0, 0%
I1: 0, 0%
C1: 0, 0%
Co-mor-
bidity (I1/
I2 / C1 /
total)
I1: nr
C1: nr
CVD - I1:
nr / I2: nr
/ C1: nr /
total: 64%
diabetic
retinopa-
thy - I1:
nr / I2: nr
/ C1: nr /
total: 19%
neuropa-
thy - I1:
nr / I2: nr
/ C1: nr /
total: 24%
nephropa-
thy - I1: nr
/ I2: nr /
C1: nr / to-
tal: 6% pe-
ripheral
macroan-
giopathy -
I1: nr / I2:
nr / C1:
nr / total:
13%
I1: nr
C1: nr
Total: hy-
perten-
sion (69%)
ischemic
heart dis-
ease (14%)
diabetic
retinopa-
thy - I1:
18% / C1:
16% / to-
tal: nr neu-
ropathy
- I1: 18%
/ C1: 16%
/ total: nr
nephropa-
thy
- I1: 8%
/ C1: 6%
/ total: nr
macroan-
giopathy -
I1: 10% /
C1: 10% /
total: nr
I1:nr
C1: nr
retinopa-
thy - I1:
124, 48%
/ C1: 147,
57%
I1: ?
C1: ?
I1: ?
C1: ?
Co-med-
ication (I1/
I2 / C1 /
total)
I1: nr
C1: nr
ACE
inhibitors -
I1: nr / I2:
nr / C1:
nr / total:
48% lipid
basal-bo-
lus insulin
- I1: 86%
/ C1: 88%
bipha-
sic insulin -
metformin
alone - I1:
5.9% / C1:
8.0% sec-
retagogue
alone - I1:
Use
of OAD -
75%: SU +
metformin
- I1: ? /
C1: ? / to-
SU only -
I1 11%
/ C1: 10%
metformin
only - I1:
8% / C1:
nr metformin
dose (g/
day) - I1:
2.28 (0.06
SE) / C1:
2.19 (0.
aspart -
I1: 26, 83.
9% / C1:
27, 87.
1% lispro
- I1: 5, 16.
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lowering
drugs - I1:
nr / I2: nr
/ C1: nr /
total: 36%
antithrom-
botic
agents - I1:
nr / I2: nr /
C1: nr / to-
tal: 34% ß-
blockers -
I1: nr / I2:
nr / C1:
nr / total:
23%
I1: 14% /
12%
28.7% /
C1: 26.5%
acarbose
alone - I1:
0% / C1:
0.4% com-
bination
therapy -
I1: 65.4%
/ C1: 65.
1%
tal 41%
SU alone -
I1: ? / C1: ?
/ total 20%
SU + acar-
bose - I1:
? / C1: ?
/ total 8%
metformin
alone - I1:
? / C1: ?
/ total 3%
metformin
+ acarbose
- I1: ? /
C1: ? / to-
tal <1%
metformin
+ other
OAD I1: ?
/ C1: ? / to-
tal <1%
other
OADs
alone - I1: ?
/ C1: ? / to-
tal <1%
insulin
+ OAD -
25%
no antihy-
pergly-
caemic
therapy -
<1%
7%
SU + met-
formin
- I1: 71%;
/ C1: 74%
TZD only
- I1: <1%
/ C1: <1%
SU + TZD
- I1: 6% /
C1: 5%
metformin
+ TZD -
I1: 3% /
C1: 3%
05 SE) sul-
fonylurea
(%) - I1:
79% / C1:
86% ACE
inhibitor
(%) - I1:
57% / C1:
55% beta-
blocker or
thi-
azide (%) -
I1: 71% /
C1: 63%
1% / C1:
4, 12.9%
glimepiride
- I1: 12,
38.7% /
C1: 14,
45.2%
metformin
- I1: 20,
64.5% /
C1: 19,
61.3%
HbA1c
[mean,
SD] (I1/ I2
/ C1 / to-
tal)
I1: 9.1%
(1.0)
C1: 9.2%
(0.9)
I1: 9.1 (1.
0)%
I2: 9.1 (1.
0)%
C1: 9.1 (1.
1)%
I1: 7.9 (1.
3)%
C1: 7.8 (1.
3)%
I1: 8.6%
(0.8)
C1: 8.5%
(0.8)
I1: 9.0%
(1.2)
C1: 8.9%
(1.1)
total: 8.9%
(1.2)
I1: 8.6%
(0.9)
C1: 8.6%
(0.9)
I1: 8.6%
(1.2)
C1: 8.5%
(1.2)
I1: 9.5%
(0.1 SE)
C1: 9.6%
(0.1 SE)
I1: 7.2%,
0.86
C1: 6.9%,
0.72
Notes
m: male
f: female
OAD(s):
oral antidi-
abetic
drugs
Even
though
it was re-
quired for
patients to
be elegible
baseline
charac-
teristics are
given
for I1: 367
and C1:
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SU:
sulphony-
lurea
?: unclear
CVD:
coro-
nary vascu-
lar disease
TZD: thi-
azolidine-
dione
nr: not re-
ported
for this
trial to be
on oral
antihyper-
glycaemic
therapy
with or
without
insulin,
the authors
report
that 0.
2% of the
included
patients
did not
have an-
tihyper-
glycaemic
therapy
at base-
line. The
reported
baseline
values refer
to 289
patient
in the
glargine
group and
to 281
patients in
the NPH
group, i. e.
compared
with the
number
of ran-
domised
partic-
ipants,
there were
4 fewer
patients
in each
group. Age
389 partic-
ipants
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range of
included
patients
was 34
to 80
years, even
though
inclusion
criteria
requiered
partici-
pants to
be 40 to
80 years of
age
Appendix 3. Adverse events
events
Charac-
teristic
Eliasche-
witz
2006
Fritsche,
2003
Haak,
2005
Her-
mansen
2006
Massi,
2003
Riddle,
2003
Rosen-
stock,
2001
Yki-
Järvinen
2006
Yokoyama
2006
Inter-
vention 1
(I1) Inter-
vention 2
(I2) Con-
trol 1 (C1)
I1:
glargine
plus
glimepiride
C1: NPH
plus
glimepiride
I1:
glargine
in the
morning
+ 3 mg
glimepiride
I2:
glargine at
bedtime
+ 3 mg
glimepiride
C1: NPH
at bedtime
+ 3 mg
glimepiride
I1: detemir
once daily
subcuta-
neously
at bedtime
or detemir
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
C1: NPH
once daily
subcuta-
neously at
bedtime or
NPH
I1: detemir
(twice
daily) plus
OAD
(met-
formin, in-
sulin secre-
tagogues,
alpha-glu-
cosidase
inhibitors)
C1: NPH
(twice
daily) plus
OAD
(met-
formin, in-
sulin secre-
tagogues,
alpha-glu-
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
vious oral
antihyper-
glycaemic
agents
continued
C1: NPH
once daily
subcuta-
neously at
bed-
time + pre-
vious oral
I1: sub-
cutaneous
glargine
once at
bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
C1: sub-
cutaneous
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
meal regu-
lar insulin
C1: NPH
once at
bedtime or
twice daily
in
the morn-
ing and
at bedtime
subcuta-
neously
I1:
glargine
once
at bedtime
plus met-
forminC1:
NPH once
at bedtime
plus met-
formin
I1:
glargine in
the morn-
ing plus as-
part
/ lispro at
each
meal with
or without
OADs C1:
NPH
at bedtime
plus aspart
/ lispro at
each
meal with
or without
OADs
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twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
cosidase
inhibitors)
antihyper-
glycaemic
agents
continued
NPH once
at bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
+ premeal
regular in-
sulin
[n] of par-
ticipants
who died
I1: 0
C1: 0
I1: 0
I2: 2
C1: 1
I1: 1
C1: 0
I1: ?
C1: ?
I1: 1
C1: 5 or 6
or 7 Total:
7 or 8
I1: ?
C1: ?
I1: ?
C1: ?
I1: ?
C1: ?
I1: ?
C1: ?
[n] adverse
events (I1/
I2 / C1 /
total)
I1: 137
C1: 150
I1: 403
I2: 414
C1: 423
P ? (“simi-
lar”)
I1: 213
[pa-
tients with
events]
C1: 103
[pa-
tients with
events]
I1: ?
C1: ?
I1: 185
[pa-
tients with
events]
C1: 193
[pa-
tients with
events]
Total: 378
[pa-
tients with
events]
nr treatment-
related ad-
verse
events - I1:
27 / C1: 20
[pa-
tients with
events]
I1: 33 [pa-
tients with
events]
C1: 24
[pa-
tients with
events]
I1: ?
C1:?
[%]
adverse
events (I1/
I2 / C1 /
total)
I1:
59% [pa-
tients with
events]
C1:
60% [pa-
tients with
events]
nr I1:
62% [pa-
tients with
events]
C1:
63% [pa-
tients with
events]
I1: ?
C1: ?
adverse
events: I1:
65% / C1:
69% [pa-
tients with
events]
events po-
tentially
related to
study med-
ication: I1:
5.5% / C1:
7.5% [pa-
tients with
events] pa-
nr treatment-
related ad-
verse
events - I1:
10.
4% / C1:
7.7% [pa-
tients with
events]
I1:
54% [pa-
tients with
events]
C1:
49% [pa-
tients with
events]
I1: ?
C1:?
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tients with
in-
jection site
reactions: -
I1: 3.1 %
/ C1: 3.9%
[pa-
tients with
events]
[n] seri-
ous adverse
events (I1/
I2 / C1 /
total)
I1: 10
C1: 10
nr I1: 22 [pa-
tients with
events]
C1:16 [pa-
tients with
events]
I1: ?
C1: ?
? nr ? I1: 1 [pa-
tients with
events]
C1: 4 [pa-
tients with
events]
I1: ?
C1:?
[%] serious
adverse
events (I1/
I2 / C1 /
total)
I1: 4.3%
C1: 4.0%
nr I1: 6.5%
C1: 9.8%
I1: ?
C1: ?
? nr ? I1:
1.6% [pa-
tients with
events]
C1:
8.2% [pa-
tients with
events]
I1: ?
C1:?
[n] drop-
outs due to
adverse
events (I1/
I2 / C1 /
total)
I1: 2
C1: 0 total:
2
hypogly-
caemic
events
- NA other
events
- NA over-
all events -
I1: 5/236 ;
I2: 4/227 ;
C1: 7/232
; Total: 16/
695 ; P = ?
(“similar”)
I1: 8
C1: 1
Total: 9
I1: 3
C1: 4
Total: 7
I1: 5 C1:
? FDR re-
port - I1: 5
/ C1: 7
hypogly-
caemic
events - I1:
1 /
C1:3 / To-
tal: 4 other
events - I1:
6 / C1:4
/ Total: 10
over-
all events -
NA
I1: 9 C1: 7
total: 16
I1: 1
C1: 1
Total: 2
I1: ?
C1:?
[%] drop-
outs due to
adverse
events (I1/
I2 / C1 /
total)
I1: 0.9%
C1: 0.0%
total: 0.4%
hypogly-
caemic
events
- NA other
events -
NA overall
events - I1:
2.1 ; I2: 1.
8 ; C1: 3.0
I1: 2.3%
C1: 0.6%
I1: 1.3%
C1: 1.7%
I1: 1.7% /
C1: 2.1%
hypogly-
caemic
events - I1:
0.3%; C1:
0.8% ; To-
tal: 0.
5% other
events - I1:
1.6% ; C1:
I1: 3.5%
C1:2.7%
Total: nr
drop-outs
due to seri-
ous adverse
events I1:
1.6% C1:
2.0%
I1: ?
C1:?
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; Total: 2.3
; p=? (“sim-
ilar”)
1.0 ; Total:
1.3% over-
all events -
NA
Notes
OAD(s):
oral antidi-
abetic
drugs
SU:
sulphony-
lurea
?: unclear
nr: not re-
ported
The
safety anal-
ysis popu-
lation in-
cluded all
ran-
domised
pa-
tients who
received at
least
one dose of
studymed-
ication
Adverse
event pro-
files were
similar be-
tween
the groups.
The only
between
treatment
differ-
ence with
a probable
relation to
trial medi-
cation con-
cerned in-
jection site
reports: I1:
13
[patients],
14 [events]
C1: 6 [pa-
tients], 6
[events]
Different
statements
are made
in this
paper con-
cerning
the par-
ticipants
who died
during
the study.
In the
paragraph
describing
the patient
flow it is
noted that
1 patient
in the
glargine
group
and 5
patients in
the NPH
group died
and an
additional
2 patients
in the
NPH
group after
discon-
tinuing
the study
medica-
tion. In
the results
section in
the safety
paragraph
the authors
98% for I1
and 93%
for C1
of the con-
firmed
symp-
tomatic
hypogly-
caemia
were
98% for I1
and 93%
for C1
of the con-
firmed
symp-
tomatic
hypogly-
caemia
were
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state that
7 deaths,
1 in the
glargine
group
and 6 in
the NPH
group
occurred
Appendix 4. Primary outcomes
Charac-
teristic
Eliasche-
witz
2006
Fritsche
2003
Haak
2005
Her-
mansen
2006
Massi
2003
Riddle
2003
Rosen-
stock
2001
Yki-
Järvinen
2006
Yokoyama
2006
Inter-
vention 1
(I1) Inter-
vention 2
(I2) Con-
trol 1 (C1)
I1:
glargine
plus
glimepiride
C1: NPH
plus
glimepiride
I1:
glargine
in the
morning
+ 3 mg
glimepiride
I2:
glargine at
bedtime
+ 3 mg
glimepiride
C1: NPH
at bedtime
+ 3mg
glimepiride
I1: detemir
once daily
subcuta-
neously
at bedtime
or detemir
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
C1: NPH
once daily
subcuta-
neously at
bedtime or
NPH
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
I1: detemir
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
C1: NPH
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
I1:
glargine
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
C1: NPH
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
I1: sub-
cutaneous
glargine
once at
bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
C1: sub-
cutaneous
NPH once
at bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
meal regu-
lar insulin
C1: NPH
once at
bedtime or
twice daily
in
the morn-
ing and
at bedtime
subcuta-
neously
+ premeal
regular in-
sulin
I1:
glargine
once
at bedtime
plus met-
forminC1:
NPH once
at bedtime
plus met-
formin
I1:
glargine in
the morn-
ing plus as-
part
/ lispro at
each
meal with
or without
OADs
C1: NPH
at bedtime
plus aspart
/ lispro at
each
meal with
or without
OADs
52Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
formin,
glitazones)
continued
at prestudy
dosages
Num-
ber (%) of
symp-
tomatic
hypogly-
caemia
pa-
tients with
episodes
I1: 122
(52.8%)
C1: 157
(62.8%)
p = 0.042
RR = 1.27
(95%CI 1.
03 to 1.57)
pa-
tients with
episodes
I1: 133
(56%)
I2: 98
(43%)
C1: 135
(58%)
p = 0.001
(I2 vs. C1)
? pa-
tients with
episodes
I1: 124
(52%) C1:
160 (67%)
episodes
I1: 519
C1: 923
pa-
tients with
episodes
I1: 35%
C1: 41%
P = ns
Episodes
per patient
/ year I1:
13.9
C1: 17.7
P < 0.02
I1: 159,
61.4%
[patients]
C1: 173,
66.8%
[patients]
Episodes
per patient
/ year: not
confirmed
I1: 5.4 C1:
8.0 p = 0.
12
confirmed
I1: 5.0 C1:
7.7
ns
I1: ?
C1:?
Num-
ber (%) of
overall hy-
pogly-
caemia
I1: nr
C1: nr
pa-
tients with
episodes
I1: 175
(74%)
I2: 155
(68%) C1:
173 (75%)
pa-
tients with
episodes
I1: 171
(50.1%)
C1: 95
(57.9%)
episodes
I1: 1507
C1: 962
pa-
tients with
episodes
I1: 151
(64%) C1:
191 (80%)
episodes
I1: 908
C1: 1688
? ? ? I1: ?
C1: ?
Episodes
per patient
/ month
I1:
0.78 (95%
CI 0.63 to
0.96)
C1:
0.79 (95%
CI 0.63 to
0.99)
Number
(%) of se-
vere hypo-
glycaemia
patients
with severe
symp-
tomatic
episodes
I1: 6 (2.
6%)
C1: 11 (4.
4%) p = 0.
303 RR=1.
02
(95%CI 0.
99 to 1.05)
pa-
tients with
episodes
I1: 5 (2.
1%)
I2: 4 (1.
8%)
C1: 6 (2.
6%)
pa-
tients with
episodes
I1: 6 (1.
8%); C1: 3
(1.8%)
episodes
I1: 7; C1: 8
pa-
tients with
episodes
I1: 1
(<1%);
C1: 6 (3%)
episodes
I1: 1; C1: 8
pa-
tients with
episodes
I1: nr (1.
7%)
C1: nr (1.
1%)
I1: 9 [pa-
tients with
events]; 14
[events]
C1: 7 [pa-
tients with
events]; 9
[events] ns
I1: 1, 0.
4%
C1: 6, 2.
3% P = 0.
0581
I1: 0
C1: 0
I1: 0
C1: 0
Num-
ber (%) of
noctur-
nal hypo-
glycaemia
pa-
tients with
confirmed
nocturnal
episodes
pa-
tients with
episodes
I1: 39
(17%)
pa-
tients with
episodes
I1: 59 (17.
3%)
pa-
tients with
episodes
I1: 71
(30%) C1:
pa-
tients with
episodes
I1: nr
(12%)
I1: 4.0
[events/pa-
tient/year]
C1: 6.
9[events/
I1: 81, 31.
3% [pa-
tients with
episode]
C1: 104,
I1: ?
C1: ?
few
episodes of
noctur-
nal hypo-
glycaemia
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I1: 39 (16.
9%)
C1: 75
(30.
0%) p<0.
010 RR=1.
19
(95%CI 1.
07 to 1.31)
I2: 52
(23%)
C1: 89
(38%) p <
0.001 (I1/
I2 vs. C1)
; C1: 46
(28.0%)
episodes
I1: 201;
C1: 112
112 (47%)
episodes
I1: 160
C1: 349
C1: nr
(24%)
P = 0.0002
patient/
year] P<0.
001
40.2%
[pa-
tients with
episode] P
= 0.0160
in either
group
HbA1c % Change in
HbA1c
from base-
line to end
of study
[mean,
SD] PP-
popu-
lation: I1: -
1.38 (1.32
SD) C1: -
1.44 (1.
33 SD) ad-
justed
mean dif-
ference: -0.
047 (90%
CI -0.232
to 0.138)
full anal-
ysis popu-
lation: ad-
justed
mean dif-
ference: -0.
029 (90%
CI -0.210
to 0.153);
p=0.8
HbA1c at
24 weeks -
[mean,
SD] I1: 7.8
(1,2) I2: 8.
1 (1,3) C1:
8.3 (1,3) P
= ? baseline
to end of
study - I1: -
1.24 I2: -0.
96 C1: -0.
84
p(I1/CI) 0.
0002 p(I2/
C1) > 0.2
percentage
of patients
achiev-
ing HbA1c
? 7.5%- I1:
43% I2:
34% C1:
33% p(I1/
CI) 0.017
p(I2/C1) >
0.2
HbA1c at
26 weeks -
I1: 7.6 (0.
1 SE) [n =
315]
C1: 7.5 (0.
1 SE) [n =
155] ?: 0.
16; 95%CI
(0.003-0.
312)
? baseline
to end of
study - I1:
-0.2; p = 0.
004 C1: -
0.4; p = 0.
0001
A1c (base-
line, coun-
try-
, and OAD
adjusted
means)
[mean, SE?
]
I1: 6.58%
(0.06 SE?)
(n = 230)
C1: 6.46%
(0.06 SE?
) (n=232)
mean dif-
ference:
0.13 (95%
CI 0.00 to
0.25)
change
of HbA1c
from base-
line to end-
point
I1: -0.46%
C1:
-0.38% P
= 0.415 by
week
52 I1: -0.
41%
C1: -0.
32%
HbA1c at
24 weeks -
I1: 7.
0 C1: 7.0 -
0.03% (-0.
13 to 0.08)
? baseline
to end of
study - I1:
-1.65 C1:
-1.59 per-
centage
of patients
achiev-
ing HbA1c
?7% with-
out noc-
turnal hy-
po-
glycaemia -
I1: 33%
C1: 27%
p<0.05
change of
Hba1c
from base-
line to end
point
I1: -0.41%
C1: -0.
59% 95%
CI (0.00 -
0.35)
HbA1c
at baseline
and end of
study
[mean, SE]
I1:
baseline -
9.13%, (0.
15 SE) end
of study -
7.14%, (0.
12 SE) C1:
baseline -
9.26%, (0.
15 SE) end
of study -
7.16%, (0.
14 SE)
HbA1c at
6 month
I1: 6.6%
C1: 7.0%
P = 0.007,
adjusted
mean
change be-
tween-
treatment
differ-
ence 0.5%
(95%CI 0.
1 to 0.8)
Notes
OAD(s):
oral antidi-
abetic
drugs
SU:
sulphony-
lurea
?: unclear
Full anal-
ysis popu-
lation in-
cluded all
ran-
domised
pa-
tients who
received
insulin de-
temir was
consid-
ered non-
inferior be-
cause the
upper limit
of the 95%
CI was < 0.
The re-
ported
results are
based on
an ITT
popu-
lation,
which is
defined as
The base-
line values
for HbA1c
given for
the ITT
groups
in Table 1
(I1: 9.5%,
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PP: per
protocol
ITT: in-
tention to
treat
at least one
dose of the
studymed-
ication and
had at least
one effi-
cacy value
recorded
during
treatment
phase
4% for the
dif-
ference in
HbA1c at
the end of
study; re-
sults of a
per proto-
col-
analysis are
reported in
the
FDA med-
ical report
- I1: 7.6%
(n=297) /
C1: 7.4%
(n=147)
all sub-
jects ran-
domised
and treated
and having
both a pre-
treatment
and an on-
treatment
value. The
size of the
ITT popu-
lation was
different
for each
variable.
Patients
with
missing
baseline
values or
no value
during
treatment
were
excluded
from
analyses.
Unfortu-
nately it
remains
unclear
how many
patients
were
considered
in the
analyses
of the
variables
of interest.
It remains
unclear
why there
are differ-
ent values
for change
of HbA1c
reported
C1: 9.6%)
differ from
the later re-
ported
baseline
val-
ues (I1: 9.
13%, C1:
9.26%)
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Appendix 5. Secondary outcomes
Charac-
teristic
Eliasche-
witz
2006
Fritsche,
2003
Haak,
2005
Her-
mansen
2006
Massi,
2003
Riddle,
2003
Rosen-
stock,
2001
Yki-
Järvinen
2006
Yokoyama
2006
Inter-
vention 1
(I1) Inter-
vention 2
(I2) Con-
trol 1 (C1)
I1:
glargine
plus
glimepiride
C1: NPH
plus
glimepiride
I1:
glargine
in the
morning
+ 3 mg
glimepiride
I2:
glargine at
bedtime
+ 3 mg
glimepiride
C1: NPH
at bedtime
+ 3 mg
glimepiride
I1: detemir
once daily
subcuta-
neously
at bedtime
or detemir
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
C1: NPH
once daily
subcuta-
neously at
bedtime or
NPH
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
I1: detemir
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
C1: NPH
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
I1:
glargine
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
C1: NPH
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
I1: sub-
cutaneous
glargine
once at
bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
C1: sub-
cutaneous
NPH once
at bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
meal regu-
lar insulin
C1: NPH
once at
bedtime or
twice daily
in
the morn-
ing and
at bedtime
subcuta-
neously
+ premeal
regular in-
sulin
I1:
glargine
once
at bedtime
plus met-
forminC1:
NPH once
at bedtime
plus met-
formin
I1:
glargine in
the morn-
ing plus as-
part
/ lispro at
each
meal with
or without
OADs C1:
NPH
at bedtime
plus aspart
/ lispro at
each
meal with
or without
OADs
Mortality
(total, dia-
betes spe-
cific and
cardiovas-
cular)
I1: 0
C1: 0
I1: 0
I2: 2
C1: 1
I1: 1
C1: 0
I1: ?
C1: ?
I1: 1
C1: 5 or 6
or 7 Total:
7 or 8
I1: ?
C1: ?
I1: ?
C1: ?
I1: ?
C1: ?
I1: ?
C1: ?
Cardiovas-
cular mor-
bidity (e.g.
not investi-
gated
nr myocardial
infarction
I1: 0 (0%)
not investi-
gated
? ?; nr ? C1: car-
diac failure
reported as
not investi-
gated
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myocardial
infarction,
stroke,
heart fail-
ure, etc)
/ C1: 1
(0.6%)
angina
pectoris
I1: 1 (0.
3%) / C1:
1 (0.6%)
coronary
artery
disorder
I1: 2 (0.
6%) / C1:
0 (0%)
myocardial
ischaemia
I1: 0 (0%)
/ C1: 1
(0.6%)
sudden
death I1:
1 (0.3%)
/ C1: 0
(0%) cere-
brovascu-
lar I1: 1
(0.3%) /
C1: 1 (0.
6%) brain
haem-
orrhage
I1: 1 (0.
3%) / C1:
0 (0%)
peripheral
ischaemia
I1: 1 (0.
3%) / C1:
0 (0%)
an adverse
event
Diabetic
late com-
plications:
renal fail-
ure, ampu-
tation,
blindness
or worsen-
ing of
retinopa-
thy
not investi-
gated
nr retinal de-
tachment
I1: 1 (0.
3%) / C1:
0
(0%) reti-
nal edema
I1: 0 (0%)
/ C1: 1 (0.
6%) retinal
not investi-
gated
? ?; nr ? not investi-
gated
not investi-
gated
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disorder
I1: 20 (5.
9%) / C1:
10 (6.1%)
neuropa-
thy I1: 0
(0%) / C1:
1 (0.6%)
Quality
of life mea-
sured with
a validated
instru-
ment
treat-
ment satis-
faction
(DTSQc)
: I1: +4.0
to 16.6 (2.
6 SD) C1:
+3.5 to 16.
0 (3.3 SD)
P < 0.02;
full analy-
sis popula-
tion
nr ? not investi-
gated
? N ? not investi-
gated
not investi-
gated
Adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
see adverse
events
Costs not
reported
nr ? not investi-
gated
? nr ? not investi-
gated
not investi-
gated
Notes
OAD(s):
oral antidi-
abetic
drugs
SU:
sulphony-
lurea ?: un-
clear
nr: not re-
ported
even
though in-
vestigated,
costs in re-
spect
to time lost
from work
or from
normal ac-
tivities due
to diabetes
illness were
not
reported
the publi-
cation does
not clarify
that values
are means
and num-
bers fol-
lowing SE
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Appendix 6. Risk of bias
Charac-
teristic
Eliasche-
witz
2006
Fritsche
2003
Haak
2005
Her-
mansen
2006
Massi
2003
Riddle
2003
Rosen-
stock
2001
Yki-
Järvinen
2006
Yokoyama
2006
Interven-
tion 1 (I1)
/ interven-
tion 2 (I2)
/ control 1
(C1)
I1: sub-
cutaneous
glargine
once at
bedtime
plus 4
mg/day
glimepiride
in the
morning
C1: sub-
cutaneous
NPH once
at bedtime
plus 4
mg/day
glimepiride
in the
morning
I1:
glargine
in the
morning
+ 3 mg
glimepiride
I2:
glargine at
bedtime
+ 3 mg
glimepiride
C1: NPH
at bedtime
+ 3 mg
glimepiride
I1: detemir
once daily
subcuta-
neously
at bedtime
or detemir
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
C1: NPH
once daily
subcuta-
neously at
bedtime or
NPH
twice daily
in
the morn-
ing and
at bedtime
+ mealtime
insulin as-
part
I1: detemir
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
C1: NPH
(twice
daily)
plus OAD
(met-
formin,
insulin
secreta-
gogues,
alpha-glu-
cosidase
inhibitors)
I1:
glargine
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
C1: NPH
once daily
subcuta-
neously at
bedtime
+ previ-
ous oral
antihyper-
glycaemic
agents
continued
I1: sub-
cutaneous
glargine
once at
bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
C1: sub-
cutaneous
NPH once
at bedtime
plus oral
antihyper-
glycaemic
agents
(one or
two of
SU, met-
formin,
glitazones)
continued
at prestudy
dosages
I1:
glargine
once daily
subcuta-
neously at
bed-
time + pre-
meal regu-
lar insulin
C1: NPH
once at
bedtime or
twice daily
in
the morn-
ing and
at bedtime
subcuta-
neously
+ premeal
regular in-
sulin
I1:
glargine
once
at bedtime
plus met-
forminC1:
NPH once
at bedtime
plus met-
formin
I1:
glargine in
the morn-
ing plus as-
part
/ lispro at
each
meal with
or without
OADs C1:
NPH
at bedtime
plus aspart
/ lispro at
each
meal with
or without
OADs
Ran-
domised
controlled
clinical
trial
(RCT)
Y Y Y Y Y Y Y Y Y
Non-
inferior-
ity / equiv-
equiva-
lence trial
? non-inferi-
ority trial
non-inferi-
ority trial
? N ? superiority
trial
superiority
trial
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(Continued)
alence trial
Controlled
clinical
trial
Y Y Y Y Y Y Y Y Y
De-
sign: par-
allel study,
crossover,
factorial
RCT
parallel
study
parallel
study
parallel
study
parallel
study
parallel
study
parallel
study
parallel
study
parallel
study
parallel
Crossover
study:
wash-out
phase
NA NA NA NA NA NA NA NA NA
Crossover
study: car-
ryover ef-
fect tested
NA NA NA NA NA NA NA NA NA
Crossover
study: pe-
riod effect
tested
NA NA NA NA NA NA NA NA NA
Method of
randomi-
sation
? ? Com-
puter gen-
erated ran-
domi-
sation list.
Block ran-
domisa-
tion within
individual
trial sites
? sequen-
tial subject
numbers
were
paired
with treat-
ment
codes, allo-
cated
at random.
The sched-
ule was
prepared
by centre
and by pre-
treatment
randomi-
sation
schedule
was gener-
ated by
Quintiles;
approx. 1:
1 ratio at
each site
? minimi-
sation of
differences
between
the study
groups
calculated
for the
following
variables
(relative
weight
of each
variable
in paren-
theses):
age (1x)
; sex (0.
5x); BMI
?
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(1.5x);
HbA1c
(1.5x);
duration
of diabetes
(0.5x);
fasting C-
peptide (1.
0x); use of
diuretics
or beta-
blocking
agents
(0.25x);
angioten-
sion-
converting
enzyme
inhibitors
(0.25x);
previous
use of a
sulfony-
lurea (2x)
Unit of
randomi-
sation (in-
dividu-
als, cluster
- specify)
? individuals individuals ? individuals individuals individuals individuals ?
Randomi-
sation
stratified
for centres
? Y ? ? Y Y ? N N
Randomi-
sation ratio
1 : 1 1 : 1 : 1 2 : 1 1 : 1 1 : 1 1 : 1 1 : 1 NA 1 : 1
Conceal-
ment of al-
location
? ? Y Y Y Y; central-
ized tele-
phone sys-
tem
Y ? ?
Stated
blinding
(open; sin-
gle, dou-
ble, triple
open open open open open open open open open
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blind)
Ac-
tual blind-
ing: partic-
ipant
NA N N NA N N N NA NA
Actual
blinding:
caregiver
/ treatment
adminis-
trator
NA N N NA N N N NA NA
Actual
blinding:
outcome
assessor
? ? ? ? ? ? ? ? ?
Ac-
tual blind-
ing: others
NA ? ? NA ? ? ? NA NA
Blinding
checked:
participant
NA NA NA NA NA NA NA NA NA
Blinding
checked:
caregiver
/ treatment
adminis-
trator
NA NA NA NA NA NA NA NA NA
Primary
endpoint
defined
(power cal-
culation)
change in
HbA1c
change of
Hba1c
from base-
line to end
point; fre-
quency
of patients
with hypo-
glycaemic
episodes
HbA1c af-
ter 26
weeks of
treatment
A1c change
of HbA1c
from base-
line to end
point
percentage
of subjects
achiev-
ing HbA1c
=<7.
0% with-
out symp-
tomatic
confirmed
noctur-
nal hypo-
glycaemia
change
of HbA1c
from base-
line to end
point
change in
HbA1c
?
[n] of pri-
mary end-
1 2 1 1 1 1 1 1 ? (1)
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point(s)
[n] of sec-
ondary
endpoints
4 4 ? 6 4 7 11 7 5
Total [n] of
endpoints
5 6 ? 7 5 8 12 8 6
Prior pub-
lication of
study
design
N N N N N N N N N
Outcomes
of prior/
cur-
rent publi-
cation
identical
Y NA NA Y NA NA NA Y NA
Power cal-
culation
Y Y Y Y Y Y Y Y N
[n] partic-
ipants per
group cal-
culated
199
(240with a
20% drop-
out rate)
199
(240with a
20% drop-
out rate)
I1: 267 /
C1: 133
198 192 375 ? 50
(55 with a
10% drop-
out rate)
NA
Non-
inferiority
trial: inter-
val
for equiva-
lence spec-
ified
Y N Y Y ? NA ? NA NA
Intention-
to-
treat analy-
sis (ITT)
Y Y Y Y Y Y Y Y ?
Per-
protocol-
analysis
Y N N Y N N N N ?
ITT
defined
Y Y Y Y Y Y Y Y N
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Analysis
stratified
for centres
N ? ? N ? Y ? Y NA
Missing
data:
last obser-
vation
carried for-
ward
(LOCF)
Y ? ? Y ? Y Y N ?
Missing
data:
Other
methods
N ? ? N ? N N N N
LOCF de-
fined
Y NA NA Y N Y Y NA NA
[n]
of screened
partic-
ipants (I1/
I2 / C1 /
total)
918 938 Total:
? (FDA sta-
tistical re-
port: 545)
735 Total: 687 I1: ?
C1: ?
Total:
1381
?
(EMEA re-
port: 846)
157 ?
[n] of eligi-
ble partic-
ipants (I1/
I2 / C1 /
total)
? 752 Total: ? 476 Total:? I1: ?
C1: ?
Total: ?
? 110 ?
[n] of ran-
domised
partic-
ipants (I1/
I2 / C1 /
total) - pri-
mary end-
point
total: 528 I1: 237
I2: 229
C1: 234
Total: 700
I1: 341
C1: 164
total: 505
(according
to the FDA
statistical
review 506
subjects
were ran-
domised
and 505
ran-
domised
and
treated)
I1: 237
C1: 239
I1: 293
C1: 285
Total: 578
I1: 372
C1: 392
Total: 764
I1: 259
C1: 259
Total: 518
I1: 61
C1: 49
I1: 31
C1: 31
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[n] of par-
tic-
ipants fin-
ishing the
study (I1/
I2 / C1 /
total)
I1: 218
C1: 244
total: 462
I1: ?
I2: ?
C1: ? To-
tal: ?
I1: 315
C1: 156
Total: 471
I1: 227
C1: 225
I1: 272
C1: 252
Total: 524
I1: ?
C1: ?
Total: ?
I1: ?
C1: ?
Total: ?
I1: 60
C1: 48
I1: ?
C1: ?
[n] of par-
tici-
pants anal-
ysed (I1/ I2
/ C1 / to-
tal)
I1: nr C1:
nr
I1: 236
I2: 227
C1: 232
Total: 695
HbA1c
- I1: 315 /
C1:
155 hypo-
glycaemia -
I1: 341 /
C1: 164
I1: 237
C1: 238
I1: ?
C1: ?
Total: ?
I1:367
C1:389
Total: 756
I1: ?
C1: ?
Total: ?
I1: 60
C1: 48
I1: ?
C1: ?
Descrip-
tion of dis-
continu-
ing partici-
pants
N N ? N N Y N Y N
Drop-outs
(reasons
explained)
protocol
violations -
I1: 4 / C1:
3 patient
wishes - I1:
4 / C1: 1
poor com-
pliance -
I1: 1 / C1:
1 lack of ef-
ficacy - I1:
1 / C1: 0
I1: ?
I2: ?
C1: ?
Total: ?
I1: ?
C1:?
Total: ?
nr adverse
events - I1:
1.7%
/ C1: 2.1%
wish to dis-
continue -
I1: 1.7% /
C1: ? poor
compli-
ance - I1:
0.3% / C1:
2.1%
I1: ?
C1: ?
Total: ?
I1: ?
C1: ?
Total: ?
nr nr
With-
drawals
(reasons
explained)
I1: 2 C1:
0no reason
stated
due to ad-
verse
events - I1:
5 / I2: 4 /
C1: 7 / to-
tal: 16
other - I1: ?
/ I2: ? / C1:
? / total: ?
adverse
events - I1:
8 (2.3%) /
C1: 2 (1.
2%) inef-
fective
ther-
apy - I1:
8 (2.3%) /
C1: 2 (1.
2%) non-
compli-
ance with
adverse
events - I1:
3 / C1: 4
ineffective
ther-
apy - I1: 0 /
C1: 1 non-
compli-
ance - I1:
1 / C1: 3
other rea-
sons - I1: 6
/ C1: 5
? withdrew
before re-
ceiving an
insulin in-
jection
- I1: 5 /
C1: 3 sub-
ject prefer-
ence - I1:
15 / C1: 3
investiga-
tors discre-
tion, poor
subject’s
wish or loss
to follow-
up - I1: 13
/ C1: 9 ad-
verse event
- I1: 9 /C1:
7no reason
reported -
I1: 6 / C1:
5
adverse
events - I1:
1 / C1: 1
nr
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pro-
tocol- I1:
1 (0.3%) /
C1: 4 (2.
4%) per-
sonal rea-
sons - I1: 6
/ C1: 1 vi-
ola-
tion of in-
clusion cri-
teria - I1:
2 / C1: 0
weight
gain - I1: 1
/ C1:
0 moved -
I1: 0 / C1:
1
ad-
herence or
lack of ef-
ficacy - I1:
3 / C1: 14
hypo-
glycaemia -
I1: 1 / C1:
3 adverse
events
other
than hypo-
glycaemia -
I1: 6 / C1:
4 protocol
vio-
lation, loss
to follow-
up and
other rea-
sons - I1: 6
/ C1: 6 no
reason re-
ported - I1:
2 / C1: 2
Losses-to-
follow-
up (reasons
explained)
I1: 1
C1: 1
I1: 1
I2: 1
C1: 0
Total: 2
I1: ?
C1: ?
Total: ?
nr ? I1: ?
C1: ?
Total: ?
I1: ?
C1: ?
Total: ?
nr nr
[n] of par-
tic-
ipants who
discontin-
ued (I1/ I2
/ C1 / to-
tal)
I1: 13
C1: 6
I1: 11
I2: 17
C1: 27
Total: 55
I1: 26
C1: 9
Total: 35
I1: 10
C1: 14
I1: ?
C1: ?
Total: ?
from all
ran-
domised
(764) pa-
tients
I1: 38/372
C1:
35/392 to-
tal: 73
I1: ?
C1: ?
Total: ?
I1: 1
C1: 1
I1: ?
C1: ?
[%]
discontin-
uation rate
(I1/ I2 /C1
/ total)
I1: 5.6%
C1: 2.4%
I1: 4.6%
I2: 7.4%
C1: 11.5%
total: 7.9%
I1: 7.6%
C1: 5.
5% Total:
6.9%
I1: 4.2%
C1: 5.9%
I1: ?
C1: ?
Total: ?
from all
ran-
domised
(764)
patients I1:
10.2C1: 8.
9 total: 9.6
I1: ?
C1: ?
Total: ?
I1: 1.6%
C1: 2.0%
I1: ?
C1: ?
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Discontin-
uation rate
similar be-
tween
groups
N N Y Y ? Y ? Y NA
[%]
crossover
between
groups
NA ? ? NA ? ? ? NA NA
Differ-
ences [n]
calculated
to analysed
patients
N N N N N N (I1: -8 /
C1: +14)
? N NA
[n] of sub-
groups
NA NA NA NA 3 NA 2 1 3
Sub-
groups:
pre-
defined
N N N N Y N 2 N 0
Sub-
groups:
post-hoc
N N N N ? N 0 N 3
[n] of sta-
tis-
tical com-
parisons
ca. 13, to-
tal number
unclear
at least 12,
total num-
ber unclear
at least 13;
total num-
ber unclear
ca. 8, to-
tal number
unclear
at least
45 (includ-
ing sub-
groups),
total num-
ber unclear
24
reported in
paper, to-
tal number
unclear
at least 16
(without
subgroup
analyses);
total num-
ber unclear
? ?
Adjust-
ment for
multiple
outcomes /
repeated
measure-
ments
?, but pri-
mary effi-
cacy vari-
able
defined
N N N ? N N Y (Bonfer-
roni)
N
Base-
line char-
acteris-
tics: Clin-
ically rele-
N N N Slight dif-
ferences re-
garding sex
whole
study pop-
ulation : N
in-
N Y Dif-
ferences re-
garding
previous
Slight dif-
ferences re-
garding sex
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vant differ-
ences
sulin naive
patients: Y
in-
sulin pre-
treated pa-
tients: Y
use of beta-
blocker or
thiazide I1:
71% C1:
63%
Treat-
ment iden-
tical (apart
from inter-
vention)
Y Y higher
daily mean
doses of as-
part in the
detemir
group after
26 weeks -
I1: 40,
2 IU/day /
C1: 35.8
IU/day)
Y ? ? ? ? (doses of
met-
formin)
N (only
glargine
group:
basal in-
sulin dose
in-
creased to
50% of to-
tal daily in-
sulin dose)
Timing of
outcomes’
measure-
ment com-
parable be-
tween
groups
Y Y Y Y Y ? Y Y Y
Compli-
ance mea-
sured
? ? ? ? ? ? ? Y ?
Other im-
portant co-
variates
measured
(specify)
? ? ? ? ? ? ? ? ?
Co-mor-
bidities
measured
? ? ? Y ? ? ? N ?
Co-medi-
cations
measured
? ? Y
for aspart;
? for fur-
ther medi-
cation
? ? ? ? ? ?
Specific
doubts
about
No infor-
mation
provided
inconsis-
tencies be-
N Y Inconsis-
tencies be-
There is a
dif-
There are
inconsis-
There are
inconsis-
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study qual-
ity
about
the 47 pa-
tients ran-
domised
but not
treated
tween re-
ported and
calculated
(from fig-
ures given
in the pa-
per) values
for HbA1c
at
endpoint
tween pa-
per and ab-
stracts
(posters)
published
elsewhere
ference in
the num-
ber of re-
ported ran-
domised
pa-
tients (259
in each
group)
, and the
sum of the
eth-
nically dif-
ferent par-
ticipants
(270 in the
glargine
group and
267 in the
NPH
group)
tencies re-
garding
the HbA1c
value
at baseline
in the table
and in the
text. Infor-
mation re-
garding
the dose of
metformin
is only pro-
vided
in the ab-
stract pub-
lication.
Unclear
if doses of
metformin
were
similar be-
tween the
groups
tencies re-
garding
the HbA1c
value in the
abstract
and the
text of the
trial. Un-
clear how
many par-
ticipants
received
OADs at
what dose,
frequency
and which
one
Fund-
ing: com-
mercial
Y Y ? ? Y Y ? Y N
Funding:
non-com-
mercial
N N ? N N N ? N N
Publica-
tion status:
peer review
journal
Y Y Y Y Y Y Y Y Y
Publica-
tion status:
jour-
nal supple-
ment
N N N N N N N N N
Publica-
tion status:
abstract
N N N previously
published
as abstract
N N N previously
published
as abstract
?
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(Continued)
Publica-
tion status:
other
N N N N N N N N N
Notes
N: no
Y: yes
OAD(s):
oral antidi-
abetic
drugs
SU:
sulphony-
lurea
?: unclear
NA: not
applicable
FPG: fast-
ing plasma
glucose
FBG: fast-
ing blood
glucose
the authors
state that
the study
had 85%
power to
de-
tect an av-
erage dif-
ference of
0.4%
in HBA1c
between
treatment
groups;
a per pro-
tocol anal-
yses is pre-
sented
in the FDA
medical re-
port;
ITT popu-
lation was
defined
as all per-
sons ran-
domised
and treated
and having
both a pre-
treatment
and on-
treatment
value. The
authors
also state
that the
size of this
popula-
tion was
different
for each
variable
but no
figures are
given for
the actual
patients
included
in the
different
analyses.
(Patients
random-
ized and
treated -
I1: 289 /
C1: 281).
The ITT
population
was used
to perform
analyses of
The re-
ported
discontin-
uation rate
(I1: 9.0% /
C1: 8.2%)
is based on
the ITT
population
and does
not in-
clude pa-
tients who
were ran-
domised
but did
not receive
study
medica-
tion. Per-
centages
of discon-
tinuation
rate in this
table were
calculated
based on
all ran-
domized
patients
Accord-
ing to the
EMEA re-
port a cen-
tralised,
comput-
erised tele-
phone ran-
domi-
sation was
used. A
higher per-
centage of
patients in
the NPH
group had
retinopa-
thy at base-
line
There are
inconsis-
tencies re-
garding
the HbA1c
value
at baseline
in the table
and in the
70Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
HbA1c,
FPG, FBG
and 24
hour blood
glucose
profiles.
The safety
population
included
all 570
random-
ized and
treated
patients.
It remains
unclear
what
parameters
(hypogly-
caemia)
were
analysed
based on
this pop-
ulation.
There is no
statement
concern-
ing spon-
sorship
in the
paper by
Massi. Yki-
Järvinen in
her paper
on the
results for
the insulin
naive
patients
informs
us that
the study
was com-
mercially
sponsored
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F E E D B A C K
Comment to the protocol by Horvath
Summary
Page 1: The general statement “evidence for the beneficial effect of antihyperglycemic therapy is conflicting” is out of date. It is
generally accepted that microvascular complications are reduced by effective glycaemic control in diabetes type 2, and there is increasing
evidence for reduction of macrovascular complications if glycaemic control is established early in the course of the disease (published
type 1 diabetes, ongoing large clinical studies in type 2 diabetes). There is no evidence “that different interventions carry different
substance specific beneficial or adverse effects”. Establishing glycaemic control in diabetes type 2 is the essential element of preventing
microvascular and macrovascular complications [by early insulin therapy, in suitable clinical conditions by oral antihyperglycemic
agents, and by combination treament]. The substance specific beneficial or adverse effects of the two classes of compounds (insulins
versus oral antidiabetic drugs, OAD) are entirely different. Within the pharmacological group of insulins, differences are related more
to the dosage form (immediate acting insulin or intermediate acting insulin) than to the specific substances (animal insulins, human
insulin or insulin analogues).
The statement “firm conclusions on the effect of interventions on patient relevant outcomes cannot be drawn from the effect.... on
blood glucose concentrations alone” is ambiguous because treatment to glycaemic targets is the primary objective in type 2 diabetes,
the effect of achieving glycaemic control on microvascular complications is firmly established.
The statement “insulin in itself is a group of heterogeneous preparations” needs to be changed to “the insulin drug substance is used
in a number of presentations of different duration of action”.
Page 2: It is useful to extend the definition of insulin analogues “changing the amino acid sequence, and the physicochemical properties”,
because the essential element is delayed absorption due to the physicochemical change.
The definition of insulin glargine needs to iinclude “which is less soluble at the injection site, and forms an amorphous precipitate
in the subcutaneous tissue which is gradually absorbed (Sandow et al 2003)”. Glargine does not form crystals or microprecipitates as
quoted in outdated reviews.
The statement in the last paragraph refers to human insulin as well as insulin analogues and can be worded “structural homology of
human insulin to insulin like growth factor (IGF-I) has caused concern...” because the findings with high (supraphysiological) doses
of human insulin in experimental preclinical studies indicate that human insulin has mitogenic activity which is dose-related, when
animals are treated with excessive doses of human insulin may cause effects similar to those of IGF-I [EPAR].
The references that “IGF-I may affect the progression of retinopathy” need to be updated in view of the clinical consensus that
progression of retinopathy is related to the rapid normalisation of glycaemic control, whereas the systemic and local factors involved
in progression of retinopathy are not completely resolved. The specific effect of IGF-I in clinical studies (Thrailkill et al 1999 ) on
formation of macular edema is not found with insulin analogues.
The statement “modified insulin analogues have shown a carcinogenic effect in the mammary gland of female rats” is not correct, there
is only one fast acting insulin analogue [B10-Asp]-insulin which has shown such an effect and was subsequently used as the comparator
for all new insulin analogues. >From the publication of Kurtzhals 2000 it is evident that all clinically used insulin analogues differ from
[B10-Asp]-insulin (which has markedly prolonged residence time on the insulin receptor) by a (rate of dissociation which is similar
to human insulin or even shorter. It cannot be justified to quote the evidence for the current insulin analogues in this rudimentary
form. No preclinical evidence has been brought forward for the “potentially adverse properties of insulin analogues”, on the contrary
extensive clinical testing and post-marketing surveillance reporting has shown no evidence for either increased mitogenic efficacy in
patients, or for progression of retinopathy and related events (retinal bleeding).
The proposed aim of the Cochrane review is to review clinical efficacy and safety. In this context, reference to the “increased mitogenic
potential” should be discontinued because the scientific evidence has been evaluated by the competent authorities (EMEA and FDA),
and periodic safety updates are evaluated which do not provide evidence or support the contentions of “increased mitogenic potential”
in the therapeutic dose range used for both type 1 diabetes and type 2 diabetes.
The inclusion criteria for studies with combination therapy should clearly state “long acting analogue combined with other antihyper-
glycaemic drugs”, and should not be limited to combination with one antihyperglycaemic drug, because the clinical study protocols
frequently included more than one orally active antihyperglycaemic drug. There are also studies comparing combination treatment
(NPH insulin plus OAD vs. long acting insulin analogue alone). Excluding such studies from the evaluation would create unnecessary
bias and loss of evidence. The clinical relevance of combination treatment reflects the reality of present-day therapy. Comparing basal
insulin therapy alone with combination therapy in RCT-24 studies is important for EBM assessment.
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The statement “only studies reporting on insulin regiments (schemata) with subcutaneous application” should be omitted because
the two long acting insulin analogues to be reviewed are approved for subcutaneous application only, both are contraindicated and
unsuitable for CSII due to their physicochemical properties.
Page 3: In the primary outcome measure, it is surprising to find hypoglycaemia events first followed by glycaemic control. The clinical
evidence is clearly that improving and maintaining glycaemic control is the key objective in type 2 diabetes (as well as in type 1 diabetes).
Prevention or a delay of progression of microvascular and macrovascular complications follows from treatment to close hypoglycaemic
targets, as defined by IDF, ADA and National Diabetes Societies. The key issue is whether glycaemic control can be achieved to the
same extent as by conventional NPH insulin, and whether the risk of hypoglycaemic events can be reduced by new treatment regimens,
using long acting insulins alone, combination with orally active antidiabetic drugs (OAD), and early insulinisation.
For the secondary outcome measure, it is suggested to evaluate first the evidence for reduced microvascular complications. This may
be followed by evaluation of reduction of macrovascular complications, for which supporting evidence from studies of “duration of 24
weeks or longer” (Page 2) cannot be expected at the present time, because longer observation periods are clearly required, as is well-
established from similar long term observations in diabetes type 1.
References: Concerning the “additional references” on pages 6 and 7 of the protocol, it is suggested to update this reference list
considerably because much of the recent evidence for effective treatment of type 2 diabetes and related studies in type 1 diabetes and
the effect on microvascular/macrovascular complications needs to be included.
It is proposed to omit reference to the “increased mitogenicity” arguments, or to include an updated and comprehensive discussion of
the topic with relevant contemporary references. [Reference and reprints forwarded by separate ma
Reply
Many thanks for your comments on this important topic.
Regarding the first comment, we will not make any changes because our interpretation of the statement that the “evidence for the
beneficial effects of antihyperglycaemic therapy is conflicting” is based on the currently published results of randomised controlled trials
dealing with drugs that lower blood glucose.
According your suggestions, we will extend the definition of insulin analogues and provide a more precise definition of insulin glargine.
Though the content of the paragraph about carcinogenicity and mitogenic potency is correct, we have rephrased it to make it more
comprehensive.
Our review will aim to assess advantages or disadvantages of long-acting insulin analogues as compared to NPH insulin. To detect any
differences between both treatment arms any additional anti hyperglycaemic agents have to be part of each treatment group.
We do not understand the comment that our statement “only studies reporting on insulin regimens with subcutaneous application”
should be omitted because e.g. studies using inhalative insulin as additional treatment in both groups will be excluded as well.
Concerning the criticism of the ranking of our outcome measures, it was the decision reached by consensus of all protocol authors in
terms of patient-relevant endpoints.
Contributors
Prof Dr Juergen Sandow. Submitter has modified conflict of interest statement: I am a member of the diabetes research group at Sanofi
Aventis.
RESPONSE TO HORVATH et al.
Summary
Horvath et al. concluded their review with the following statement “If at all, only a minor clinical benefit of treatment with long-
acting insulin analogues (LAIA) for patients with diabetes mellitus type 2 treated with ”basal“ insulin regarding symptomatic nocturnal
hypoglycaemic events. Until long-term efficacy and safety data are available, we suggest a cautious approach to therapy with insulin
glargine or detemir.”
We believe this interpretation is overly critical of the long-acting analogues, and fails to take into consideration some important
points. Defined as a “minor clinical benefit”, the consistent finding of reduced risk of hypoglycaemia with LAIA reflects the authors’
preconceived bias that contradicts the very essence of the Cochrane reviews, and it disregards the importance of hypoglycaemia in
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clinical diabetes. Firstly, hypoglycaemia is not a trivial problem from the point of view of many patients and physicians, and is a leading
barrier to effective use of insulin.
The widespread use of both glargine and detemir has occurred in part due to the experience, both in studies and in clinical practice,
that hypoglycaemia is reduced when they are used instead of human intermediate insulins. However, the authors counter this beneficial
effect of LAIA in their discussion, using the argument that there is a possibility of bias because the studies were not blinded. Although
lack of blinding is a conventional objection that might have influenced hypoglycaemia reporting, measurements of glucose confirming
hypoglycaemic events are quite objective and less likely to be affected by lack of blinding of treatment. In fact, blinding was not possible
owing to the cloudy physical characteristics of NPH and the clear nature of the soluble LAIAs that have consistently shown less frequent
hypoglycaemic events.
Secondly, with regards to the methodology of the paper, most of the studies selected were equivalence studies or non-inferiority
trials performed as required for regulatory approval. Thus, not surprisingly, if the hypothesis that preceded the meta-analysis was to
demonstrate HbA1c superiority of LAIAs over NPH, this was not found because it was not the intent, nor was it in concordance with
the objective of the majority of the published study data used for the analysis. Moreover, the differences in hypoglycaemia observed
between human insulins and insulin analogues are greater as glycaemic control approaches the usual target levels, HbA1c 7.0 or 6.5%.
Non-inferiority studies generally do not aim to optimize control, and therefore may minimize this advantage. A statistical analysis of
this problem of interpretation has recently been published (Mullins et al, 2007) and is very relevant to the conclusions of the meta-
analysis. A leading point is that when rates of hypoglycaemia are adjusted for baseline or achieved HbA1c levels, differences between
human insulin and analogues become more apparent.
Thirdly, the authors stated that “no trial reported data on quality of life”. We believe this is misleading and inaccurate, as aspects of
quality of life, such as treatment satisfaction, have been reported at various congresses with full reports in progress. Data sets would have
been fully available from the sponsors had the authors requested them. Their findings are consistent with the study by Eliaschewitz,
which is cited in the review.
Finally, the secondary endpoints of the meta-analysis were mortality/cardiovascular morbidity/diabetic late complications. The studies
analysed did not aim to investigate these variables and their duration was not long enough to take these into consideration. Even
though the authors acknowledge this in their discussion, they still conclude that no important improvements in the development of
microvascular complications would be expected from treatment with LAIAs. This is correct because there is no reason to believe that
these new insulins should have any intrinsic or direct effect to benefit complications. What it is incorrect is to advise caution in the
conclusion when using LAIA. Caution implies by definition “avoiding danger or harm; close attention or vigilance to minimize risk”.
We think this advice is premature, and the evidence for potential harm is scanty and should not have been given a place in their
conclusion. Any strong remarks or recommendations based on theoretical risks of LAIAs should await completion of ongoing outcome
studies on retinopathy and cardiovascular parameters, and results fully analyzed and published.
In conclusion, we believe the clinical benefits of LAIA over NPH insulin are more than “minor” in many situations, and that the advice
to use LAIAs with “caution” is not warranted and is inappropriate on the basis of existing findings. Long-acting insulin analogues
are widely used tools that have facilitated insulin management to achieve glycaemic control more safely and more predictably with
significantly less risk of hypoglycaemia, allowing more active self-titration by patients with type 2 diabetes. Ongoing studies will provide
more complete answers to the questions about long-term risks and benefits of these agents, and will allow more definitive conclusions.
References
Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated
hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine
Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619.
Reply
We thank Drs. Rosenstock, Fritsche and Riddle for their interest in our review and their comments.
We agree that hypoglycaemia is indeed an important clinical problem affecting the wellbeing and treatment satisfaction of patients, and
the extent to which blood glucose concentration can be lowered. Indeed, the effectiveness of insulin therapy can only be evaluated by
consideringHbA1c change and the corresponding number of hypoglycaemic events together. The fact that we considered hypoglycaemia
as being of high importance is also reflected by the fact that we chose the “number of overall, severe and nocturnal hypoglycaemia”
(along with HbA1c) as our primary endpoint.
Also it seems that those same considerations were the basis for conducting the non-inferiority trials at hand: with the same efficacy in
reducing HbA1c (non-inferiority) an additional benefit of reduced hypoglycaemic events was expected. Since for our review lowering
HbA1c was not the sole crucial endpoint, but corresponding hypoglycaemia rates were considered as important, the inclusion of non-
inferiority trials does not undermine the conclusions that can be drawn from our results.
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At any rate, it is essential that the studies were conducted in such a way, that results could be considered largely as unbiased. Among
those items that determine the methodological quality of trials is blinding of patients and caregivers for treatment.
It is true that blinding was not feasible in the studies comparing insulin glargine or detemir with NPH-insulin. However, the simple
fact that patients and caregivers were not blinded, does raise the risk for bias regardless of whether blinding would have been possible
or not. Also in a situation where blinding is not possible or feasible, other precautionary measures, such as adequate concealment of
allocation, blinding of endpoint assessment or unequivocal definitions of endpoints have to be taken to minimize the chance for bias.
In most of the included studies either this was not done or not reported (see also Table 03 “Study quality” and Table 07 “definition
of hypoglycaemia in study as reported”). Also, the lack of blinding was not the only item leading us to conclude that methodological
quality was insufficient to rule out bias. Thus, from the information which is available to us, we have to conclude that the results are
open for bias.
“Quality of life” is a multidimensional construct. While quality of life and health status instruments are measuring the outcomes of
treatment, treatment satisfaction instruments assess the level of satisfaction with health status outcomes (Revicki 2008). Differentiating
between these two concepts, the published trials did not provide any information on aspects of quality of life. However, we still reported
the results on treatment satisfaction.
We also contacted all authors of the included studies, among them Drs. Rosenstock, Riddle and Fritsche, asking for additional
information. Not all responded. Among those who did was Dr. Riddle. In his letter he told us, that although he had the information we
were asking for, he was not able to disclose them to us, because it was the property of Sanofi-Aventis. We also contacted the producers
of long-acting insulin analogues “Sanofi-Aventis” and “Novo Nordisk”. In the answering letter from Sanofi Aventis (Dr. Vaur) we were
told: “With respect to this request I must unfortunately inform you that our company policy is to not provide any third parties with
our confidential information such as, e.g. unpublished information contained in study reports or study databases.” We did not receive
an answer from Novo Nordisk. In contrast, some authors did provide us with additional data which we incorporated in the review -
we also acknowledged this wherever applicable.
For insulin therapy in diabetes mellitus, NPH is an effective, safe substance which has been tested over decades. In such cases where
a proven effective therapy is available, the introduction of new substances should only be advised if there is a major improvement in
efficacy, or if the new substance is proven both effective and safe. Introducing new substances while safety issues are still unanswered
could result in harm to patients, as the examples of rosiglitazone, vioxx and others show. So, our advocacy of a cautious approach to
therapy with long-acting insulin analogues at this time is justified.
Karl Horvath
Klaus Jeitler
Andrea Berghold
Susanne Ebrahim
Thomas W. Gratzer
Johannes Plank
Thomas Kaiser
Thomas R Pieber
Andrea Siebenhofer
(Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. GUT online 2008.)
Contributors
Julio Rosenstock, Andreas Fritsche, Matthew Riddle
Submitter has modified conflict of interest statement:
Julio Rosenstock has received grants for research from and/or has been a consultant to Amylin, Boheringer-Ingelhein, Bristol-Myers
Squibb, Centocor, Eli Lilly, Emisphere, GlaxoSmithKline, Johnson & Johnson, MannKind, Merck, Novartis, NovoNordisk, Pfizer,
Roche, Sankyo, sanofi-aventis and Takeda. Andreas Fritsche has received honoraria for lectures from sanofi-aventis, MSD,NovoNordisk
and Bayer. Matthew Riddle has received grant/research support from Amylin, Eli Lilly and sanofi-aventis, has been a consultant to
Amylin, Eli Lilly, NovoNordisk, sanofi-aventis and Valeritas, and has received lecture honoraria from Amylin, Eli Lilly and sanofi-
aventis
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